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I – INTRODUCTION 
1.1. Complex Regional Pain Syndrome 
Complex regional pain syndrome (CRPS) is a painful condition affecting one or 
more extremities of the body, marked by a wide variety of symptoms and signs. 
The syndrome was first described as causalgia by Silas Weir Mitchell in 1865 
during the American Civil War in soldiers who developed burning pain and trophic 
disturbances after gunshot wounds associated with nerve injuries. In 1900, Paul 
Sudeck, a german surgeon, described a similar syndrome with pain, edema and 
trophic changes after a limb trauma without nerve lesion, and termed as post 
traumatic bone dystrophy. He was the first to hypothesize on the pivoting role of an 
inflammatory process. As the sympathetic nervous system seems to be overactive 
at the first glance, the term reflex sympathetic dystrophy was used for many years. 
The descriptive term CRPS was then established after some studies questioned 
the role of sympathetic nervous system in the pathophysiology of this condition 
(Stanton-Hicks, Janig et al. 1995). Two types of CRPS are distinguished: CRPS 1 
without and CRPS 2 with clinically evident peripheral nerve lesion. There is neither 
clinical nor pathological evidence to suggest that the mechanisms are any different 
in these two types of CRPS, and the response (or lack thereof) to treatments are 
similar (Oaklander; Oaklander and Fields 2009; Oaklander 2010). The disease 
course varies from relatively mild and self-limiting to a chronic devastating disease 
with a high impact on the daily functioning and quality of life of the patients, 
associated with a substantial enhancement of societal and economic burdens 
(Albrecht, Hines et al. 2006). 
1.1.1. Incidence 
Few prospective, epidemiological studies have been published on CRPS; 
nevertheless, population-based cohort studies estimate its incidence between 5.46 
in the U.S.A. and 26.2 in the Netherlands per 100,000 person per year (Sandroni, 
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Benrud-Larson et al. 2003; de Mos, de Bruijn et al. 2007). This discrepancy might 
be due to differences in population characteristics or diagnostic criteria applied. 
Both European and North American studies agree that the upper extremities are 
more affected than the lower extremity. Women are clearly more affected than men 
with a ratio of 3-4:1, and the peak of incidence lies between 50 and 70 years of 
age. Menopausal woman between 61–70 years appeared to be at the highest risk 
for the development of CRPS. It appears though frequently in almost every age 
group except children. CRPS type 1 has been described in children, but the 
incidence is much lower than in adults. The risk is considered to be much higher in 
certain subgroups of patients exposed to a trauma or surgery, exceeding 30% 
following some surgical procedures or fracture (Sandroni, Benrud-Larson et al. 
2003; de Mos, de Bruijn et al. 2007). 
1.1.2. Etiology 
One exact initial event in CRPS is not yet known. There have been reported a 
number of events that can lead to CRPS. Most authors agree that the common 
event is a physical injury affecting the distal part of an extremity. The symptoms 
exceed in both magnitude and duration the expected clinical course of the inciting 
event, and often result in a significant impairment of motor function. Symptoms 
appear in one or more extremities after even a relative mild trauma, or many times 
spontaneously with no association with previous inciting injury. In many cases 
patients are not able to relate any initial event to the onset. Fracture is the most 
common precipitating event (44%) beside post-surgical conditions, contusions, and 
strain or sprain. Less common causes are central nervous system lesions, 
including spinal cord injuries and cerebrovascular accidents (Braus, Krauss et al. 
1994; Kocabas, Levendoglu et al. 2007; Chae 2010), and cardiac ischemia 
(Ahmed 2003). A variety of other events have been lately related to the onset of 
CRPS such as infections (van de Vusse, Goossens et al. 2001; Goebel, Vogel et 
al. 2005; Gross, Tschernatsch et al. 2007) or autoimmune diseases (Ostrov, 
Eichenfield et al. 1993; Tsutsumi, Horita et al. 1999; Ahmed 2003; Schwartzman, 
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Gurusinghe et al. 2008). Recently, some studies demonstrated familial occurrence 
of CRPS as well (Shirani, Jawaid et al.; de Rooij, de Mos et al. 2009). 
1.1.3. Pathogenesis and mechanisms 
How CRPS sometimes progresses into being such a destructive condition is not 
clearly known. It is difficult to explain how a possible initial minor injury can result in 
a condition with far greater pain and discomfort well after this initial injury has 
healed. There are a number of hypotheses on the pathophysiology of CRPS based 
on recent experimental and clinical findings. However, all studies on the 
pathophysiology revealed that the mechanisms are multifactorial and complex, and 
therefore not completely understood (Bruehl 2010). The following mechanisms 
have been identified: (1) Exaggerated inflammation after trauma, in particular a 
neurogenic inflammation at the site of the lesion disturbing the somatic sensation, 
(2) hypoxic changes, (3) dysfunctions of the peripheral or central sympathetic 
nervous system, and (4) profound cortical reorganization processes (see Figure 1) 
(Wasner, Schattschneider et al. 2001; Huygen, De Bruijn et al. 2002; Leis, Weber 
et al. 2003; Maihofner, Handwerker et al. 2003; de Mos, Sturkenboom et al. 2009). 
Certain mechanisms seem to predominate depending on clinical presentation or 
CRPS stage (Eberle, Doganci et al. 2009). Additionally, there is increasing 
evidence of an involvement of the immune system as pivotal mechanism in CRPS. 
Since the first description of the disease 150 years ago, the development of these 
dysfunctions in only a part of trauma patients remains obscure.  
1.1.3.1. Inflammation, neurogenic inflammation and hypoxic changes 
Paul Sudeck already hypothesized in his first description on the pivotal role of an 
inflammatory process. He described in the clinical picture of CRPS the major signs 
of inflammation - calor, rubor, dolor and functio leasa - as an indication that at least 
in the initial phase of the disorder an inflammatory process is playing a role in the 
pathophysiology of this condition (Sudeck 1900). Classic inflammation is marked 
by the presence of proinflammatory cytokines. In CRPS, analysis of blister fluid 
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from the affected limb revealed increase of the cytokines TNFα, IL-6 and tryptase 
(a product of mast cell degranulation) (Huygen, De Bruijn et al. 2002). IL-1 and IL-6  
were also found to be increased in spinal fluid (Alexander, van Rijn et al. 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Possible interaction between pathogenic mechanisms that might lead to the florid clinical 
picture of CRPS. (Extracted from (Bruehl 2010)). CGRP, calcitonin gene-related protein; IL, 
interleukin; TNFα, tumor necrosis factor alpha. 
Additionally to classical inflammation, a neurogenic inflammation is an important 
local abnormality observed in CRPS (Vacariu 2002). It is characterized by release 
of neuropeptides from afferent (and nociceptive) nerve endings causing 
inflammatory effects such as edema, increased permeability of blood vessels, and 
histamine release from mast cells (Weber, Birklein et al. 2001). Neuropeptides are 
thought to be released mainly by “sleeping” nociceptors. Trauma and the following 
release of inflammatory mediators “wake up” these afferent fibers leading to long-
term sensitization of nociceptors mediated by neuropeptides including substance 
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P, calcitonin gene related peptide (CGRP), neuropeptides Y, bradykinin and 
vasoactive intestinal protein. While a limited inflammatory response is expected 
after trauma, studies have demonstrated robust and persistent amplification of 
cytokine (Wesseldijk, Huygen et al. 2008), endothelin-1 (Groeneweg, Huygen et al. 
2006) and neuropeptides (CGRP, substance P) (Birklein, Schmelz et al. 2001; 
Weber, Birklein et al. 2001) signaling in patients who developed CRPS after injury. 
Recently, a loss of inhibition of these neuropeptides has been suggested to explain 
at least a part of CRPS symptoms (Birklein and Kingery 2009). Deficiency or 
blockage of peptidases such as neutral endopeptidase and angiotensin converting 
enzyme, which participate in the post-release and degradation of neuropeptides, 
has been implicated to predispose to CRPS (Kramer, Schmidt et al. 2005; de Mos, 
Huygen et al. 2009; Kramer, He et al. 2009). Moreover, endothelial dysfunction, 
hypoxic changes, and free radical damage have also been suggested as important 
processes in the pathogenesis of CRPS. An impaired microcirculation as a result of 
free radicals, lactate acidosis and altered nitric oxide synthesis after inflammation 
and ischemia seems to underlie a cold extremity that is observed in some CRPS 
patients (de Mos, Sturkenboom et al. 2009). 
1.1.3.2. Autonomic nervous system dysregulation  
Most authors suggest CRPS to be a syndrome where the autonomic nervous 
system is “out of control”. Disturbances of the sympathetic nervous system were 
classically supposed as main feature of CRPS. Changes in skin blood flow, 
temperature, and sweating as well as the symptom of sympathetically maintained 
pain have been ascribed to sympathetic dysregulation in CRPS.  
Physiologically, sympathetic preganglionic neurons, which are involved in 
regulation of effector cells in somatic tissues, project to the paravertebral ganglia of 
the sympathetic trunk and synapse with postganglionic neurons that innervate the 
effector cells. These preganglionic sympathetic neurons are under central control 
originating in the hypothalamus, and the pattern of ongoing and reflex discharges 
is characteristic for each type of sympathetic pathway, e.g., skin vasoconstrictor, 
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muscle vasoconstrictor and sudomotor neurons, and varies according to the 
innervated target cells. Sympathetic vasoconstrictor pathways that regulate 
cutaneous blood flow are mainly under thermoregulatory as well as respiratory 
control. Under normal condition sympathetic activity does not interact with the 
nociceptive neurons in the periphery (Wasner 2010). 
Sympathetically maintained painful sensations described in CRPS are provoked by 
sympathetic outflow through sympathetic-afferent coupling in which adrenergic 
receptors are expressed on primary afferent nerve endings. The sympathetic 
hyperactivity was the traditional rationale for clinical use of selective sympatholytic 
blockers in CRPS. Indeed, pain, in a subset of CRPS patients, can be relieved by 
blockage of the efferent sympathetic nerve supply to the affected limb 
(Schattschneider, Binder et al. 2006). Moreover, it is known that after injury new 
communication pathways are formed between sympathetic terminals and sensory 
neurons (Watkins and Maier 2002). This underlying sympathetic sprouting in the 
dorsal horn and/or in the skin has been referred to as one explanation for the 
pathogenic sympathetic activity in CRPS. 
The common autonomic features of CRPS, such as cool, bluish limb as a result of 
vasoconstriction also reflect excessive sympathetic outflow. However, most CRPS 
patients in early acute stages often show increased skin temperature associated 
with increased sweating. This pattern of excessive functional inhibition of 
cutaneous sympathetic activity associated with enhanced sympathetic sudomotor 
activity in the affected limb suggest a profound inhibition of central sympathetic 
structures leading to thermoregulatory dysfunction (Birklein, Riedl et al. 1998).  
Further studies have given strong evidence that sympathetic vasoconstrictor 
activity is inhibited rather than enhanced in acute CRPS (Wasner, Heckmann et al. 
1999). Profound vasodilatation due to neurogenic inflammation interferes with 
sympathetic outflow and mimic loss of vasoconstrictor response. Sympathetic 
vasoconstrictor reflexes and venous levels of norepinephrine and its metabolites 
are diminished as a result of decreased release of transmitter from postganglionic 
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sympathetic fibers on the affected side (Wasner, Schattschneider et al. 2001).  
Some authors suggest that decrease in blood flow and skin temperature often 
observed in late stages might reflect an secondary adrenergic supersensitivity, 
consequence of receptor upregulation that occur in response to the initial functional 
inhibition of vasoconstrictor activity and diminished levels of neurotransmitters 
observed in the acute stage (Baron and Maier 1996). This secondary hyperactivity 
could lead to cold bluish affected limb, even though sympathetic neuronal activity is 
reduced (Wasner 2010). 
1.1.3.3. Sensitization and cortical reorganization 
The peripheral alterations give rise to a series of changes at the level of the central 
nervous system. The neural plasticity that happens after an injury, described as the 
capacity of neurons to change their structure and functional profile, is mediated by 
the neuropeptides described above, and is implied as one mechanism behind the 
sensorial disturbances in CRPS. Sensitization leads to painful response to a 
normally not painful stimulus, resulting in allodynia and hyperalgesia. CRPS patient 
display an increased excitability of spinal cord neurons to repeated stimuli applied 
to the affected limb in comparison to the contralateral side (Bruehl 2010). 
Following the central sensitization, alterations at the supraspinal level might evolve, 
resulting in the altered sensory mapping in the cerebral cortex observed in CRPS 
patients. Neuroimmaging studies showed a reduction in size of the representation 
of the CRPS-affected limb in the somatosensory cortex compared with the non-
affected limb (Juottonen, Gockel et al. 2002; Maihofner, Handwerker et al. 2003; 
Pleger, Ragert et al. 2006). This might implicate an additional contribution to the 
sensational disturbance in CRPS (Juottonen, Gockel et al. 2002; Maihofner, 
Handwerker et al. 2003; Pleger, Ragert et al. 2006). Recently, an altered central 
opioidergic neurotransmission has been described (Klega, Eberle et al. 2010). 
However, the importance of the cortical reorganization and central alterations in 
CRPS remains controversial, and is currently under investigation. The origin and at 
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which point in the development of CRPS somatotopic reorganization occurs is not 
known (Bruehl 2010).  
1.1.3.4. Possible involvement of the immune system 
Some studies showed an increasing evidence for the involvement of the immune 
system in the physiopathology of CRPS. The HLA alleles DQ1, DR13, DR15 and 
the centromeric regions of the HLA class 1 antigens were linked to CRPS (Kemler, 
van de Vusse et al. 1999; van de Beek, Roep et al. 2003). Local and systemic 
disturbances of the cytokine network have been described, and raised up the idea 
of an immune-mediated process (Kemler, van de Vusse et al. 1999; Huygen, De 
Bruijn et al. 2002; Alexander, van Rijn et al. 2005; Maihofner, Handwerker et al. 
2005). Analysis of blister fluid of affected extremities, venous blood and liquor 
revealed a pro-inflammatory cytokine expression profile indicating an ongoing 
immune process, and reinforce that the immune system might play an 
underestimated role in CRPS (Maihofner, Handwerker et al. 2005; Alexander, 
Perreault et al. 2007). Additionally, one study showed evidence of an enhanced 
immune cell activation with migration of leukocytes and nonspecific 
immunoglobulins (IgG) towards the CRPS affected limb (Tan, Oyen et al. 2005). 
Notwithstanding controversial reports about the efficiency of corticosteroids, some 
patients with acute CRPS could be sufficiently treated by using systemic 
corticosteroids (Christensen, Jensen et al. 1982; Braus, Krauss et al. 1994; Zyluk 
and Puchalski 2008). Additionally, an improvement of CRPS after treatment with 
the TNF-α antagonist infliximab or intravenous immunoglobulins (IvIg) has been 
observed in some cases (Huygen, Niehof et al. 2004; Goebel, Vogel et al. 2005; 
Bernateck, Rolke et al. 2007; Goebel, Baranowski et al. 2010). 
Autoantibodies specifically targeting autonomic (e.g. sympathetic) nervous system 
structures have been demonstrated in our group for the first time (Blaes, Schmitz 
et al. 2004). These autoantibodies, detected by immunofluorescence, have been 
found to be directed against antigens of sympathetic ganglia neurons. Additionally, 
Goebel et al. (2005) could also demonstrate increased binding of CRPS sera to 
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various peripheral and central nervous system structures (Goebel, Vogel et al. 
2005). These autoantibodies might be transferable since IgG derived from CRPS 
serum samples, which was injected in mice, led to abnormal behaviour (Goebel, 
Stock et al. 2005). The underlying antigens and the pathophysiological role of 
autoantibodies are entirely unknown.  
1.1.4. Clinical features 
Many symptoms observed in CRPS patients are normal during the recovery period 
of a trauma or a surgical procedure. The characteristic feature of CRPS is that this 
normal reaction does not stop; the normal inflammation seems to continue and 
gets out of control. 
The most prominent feature is pain, including spontaneous pain, allodynia and 
hyperalgesia. Additionally, the affected extremity can display autonomic 
abnormalities e.g. changes in color and/or temperature (vasomotor disturbances), 
edema, alterations in transpiration (sudomotor disturbances), trophic changes such 
as abnormal hair and nail growth; and, muscular atrophy and/or dysfunction 
(motortrophic disturbances).  
 
 
 
 
 
 
 
 
 
Figure 2. Picture of moderate (left) and severe (right) CRPS on the upper limb. Debilitating pain, 
edema and trophic changes impairs the function of the affected limb and consequently the quality of 
life in both cases (extracted from www.foot-pain-explained.com/CRPS.html and 
http://en.wikipedia.org/wiki/File:Severe_CRPS.jpg). 
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The initial stage of the disease is characterized by the appearance of the major 
signs of inflammation: calor, rubor, dolor and functio leasa. The functionality of the 
affected limb is often impaired. The most important sensory disturbances are pain 
and hyperalgesia. The patients report often burning spontaneous pain in the distal 
part of the affected limb, sometimes the pain has an aching or pricking character. 
Nearly all patients experience hyperalgesia, basically to thermal stimuli or 
mechanical impact. Hyperalgesia to cold is significantly more frequent, and is 
regarded as a symptom of sympathetically maintained pain. Sensory disturbances 
appear usually in early stages, are predominantly distally located, and display no 
consistent spatial relationship to individual nerve territories or to the site of the 
inciting lesion. 
In addition, motor symptoms are usually present from the beginning (Veldman, 
Reynen et al. 1993; Birklein and Handwerker 2001), and may progress with 
ongoing duration (van Hilten, van de Beek et al. 2000). Weakness of all muscles of 
the affected distal extremity is present in 77% of CRPS patients. Small accurate 
movements and range of motion are often impaired. In acute cases movement 
limitations are determinated by edema and in chronic stages by atrophic changes, 
especially on palmar and plantar sides of hands and feet. About 50% of the 
patients have a postural or action tremor; and, 5-10% of patients develop dystonia 
of the affected hand or foot (van Hilten 2010) (Figure 3).  
 
 
 
 
 
 
 
Figure 3. Extremity dystonia in CRPS patients (Extracted from (van Hilten 2010).  
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During the acute stage the affected limb is usually red and hot, warmer than the 
contralateral limb. Additionally, edema and sweating abnormalities like hyper- or 
hypohidrosis are pronounced, and affect almost all CRPS patients. Later on in 
chronic stages, the affected skin turns to bluish and cold; however, 30% percent of 
all patients have a decreased skin temperature from the beginning and usually stay 
cold in CRPS course. The typical temperature difference between affected and 
unaffected side is more than 1 ºC. 
Three stages of CRPS have been classified. Although a consensus panel 
recommended that staging be eliminated, it is important to have an awareness of 
potential disease progress. Disease progress is very variable. 
Stage I or early CRPS: This stage is chracterized by severe pain, more 
than what would be expected from the injury, with a burning or aching quality. It 
may be increased by dependency of the limb, physical contact, or emotional upset. 
The affected area becomes edematous, may be hyperthermic or hypothermic, and 
shows increased nail and hair growth. Radiographs may show early bony changes. 
Duration is usually 3 months from onset of symptoms. Some patients remain in one 
stage or another for many months or even years. They may never progress or they 
may progress quickly to late stage. Physical findings may be minimal, especially in 
those who remain in stage I or progress slowly.  
Stage II or established CRPS: As diseases progresses, affected area 
becomes indurated, cool and hyperhidrotic with livedo reticularis or cyanosis. Hair 
may be lost, and nails become ridged, cracked, and brittle. Hand dryness becomes 
prominent, and atrophy of skin and subcutaneous tissues becomes noticeable. 
Intense debilitating pain remains the dominant feature. It usually is constant and is 
increased by any stimulus to the affected area. Stiffness of affected limb develops 
at this stage. Radiographs may show diffuse osteoporosis. Duration is usually 3-12 
months from onset.  
Stage III or late CRPS: In the late stage pain starts spreading proximally. 
Although it may diminish in intensity, pain remains a prominent feature. Flare-ups 
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may occur spontaneously. Irreversible tissue damage occurs. Skin is thin and 
shiny. Edema is absent. Contractures may occur. Radiographs indicate marked 
demineralization. 
1.1.5. Diagnosis 
Until the present date, there is no objective diagnostic method to confirm the 
diagnosis of CRPS. Diagnosis is possible based on the clinical presentation of the 
syndrome. The clinic of CRPS is based on the findings during the history and 
physical examination, for which several diagnostic criteria sets have been 
developed. According to the International Association for the Study of Pain (IASP), 
established during a consensus of experts in 1994 (Merskey and Bogduk 1994), 
the diagnosis of CRPS can be made if the following criteria are fulfilled: 
1. The presence of an initiating noxious event, or a cause for immobilization, 
without (CRPS 1) or with nerve lesion (CRPS 2); 
2. Spontaneous pain or hyperalgesia/hyperesthesia not limited to a single 
nerve territory and disproportionate to the inciting event in severity; 
3. Evidence at some time of edema, changes in skin blood flow (temperature) 
or sudomotor abnormalities, motor symptoms or trophic changes are 
present on the affected limb, in particular at distal sites; 
4. Exclusion of conditions that would otherwise account for the degree of pain 
and dysfunction.  
The IASP criteria are the most widely accepted. However, these criteria were never 
fully validated. Many studies have reported high sensitivity (0.98) which makes 
them valuable for clinical use but the low specificity (0.36) limits its use for research 
purpose (Bruehl, Harden et al. 1999). In the practice, the application of IASP 
criteria may result in the overdiagnosis of CRPS due to a poor specificity. The 
combination of multiple elements like vasomotor, sudomotor and edema-related 
changes into one diagnostic criterion, and the failure to include motor/trophic 
changes has been reported to be responsible for the limited specificity of the IASP 
criteria. For research purpose a more restricted definition made by Bruehl and 
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co-workers (1999) (Bruehl, Harden et al. 1999) has been recommended. These 
authors proposed extra criteria in which the patient tells his/her own story about the 
complaints, and the observer confirms a number of these complains by physical 
examination. The proposed modified diagnostic criteria for CRPS extracted from 
Bruehl et al. (1999) include the following extra criteria: 
1. Continuing pain which is disproportionate to any event 
2. Must report at least one symptom in each of the following four categories: 
o Sensory: Reports of hyperesthesia and/or allodynia 
o Vasomotor: Reports of temperature asymmetry and/or skin colour 
changes and/or skin colour asymmetry 
o Sudomotor/edema: Reports of edema and/or sweating changes 
and/or sweating asymmetry 
o Motor/trophic: reports of decreased range of motion and/or motor 
dysfunction (weakness, tremor, dystonia) and/or trophic changes 
(hair, nail, skin) 
3. Must display at least one sign in two or more of the following categories: 
o Sensory: evidence of hyperalgesia (to pinprick) and/or allodynia (to 
light touch) 
o Vasomotor: evidence of temperature asymmetry and/or skin colour 
changes and/or asymmetry 
o Sudomotor/edema: evidence of edema and/or sweating changes 
and /or sweating asymmetry 
o Motor/trophic: evidence of decreased range of motion and/or motor 
dysfunction (weakness, tremor, dystonia) and/or trophic changes 
(hair, nail, skin) 
These criteria lead to a gain in specificity (0.94) of the IASP criteria, and thus 
improve the ability to discriminate accurately between CRPS and other types of 
neuropathic pain. For that, it should be observed at least one symptom in all four 
symptom categories and at least one sign (at evaluation) in two or more sign 
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categories, as revised by Harden and co-workers (Harden, Bruehl et al. 2007).  
1.1.6. Treatment 
The treatment of CRPS still is an interdisciplinary challenge. Because there is no 
cure, treatment is aimed at relieving painful symptoms. Most of the treatment 
regimens including analgesics, antiepileptics, or antidepressants are only 
symptomatic treatment. These treatment strategies have failed to produce 
consistent long-lasting improvement in symptoms. Other treatments include 
physical therapy, sympathetic nerve block, spinal cord stimulation, intrathecal drug 
pumps to deliver opioids and local anesthetic agents via the spinal cord; and, as a 
last resort for pain relief, amputation of the affected extremity (Albrecht, Hines et al. 
2006). Corticosteroids have been used successfully in some small studies 
(Christensen, Jensen et al. 1982; Braus, Krauss et al. 1994; Zyluk and Puchalski 
2008). Huygen and co-workers reported successful treatment of CRPS with a TNF-
α antagonist infliximab in a small study (Huygen, Niehof et al. 2004); these authors 
failed to confirm this effect in a controlled study using TNF-α antagonist (personal 
communication). Improvement of CRPS after treatment with IvIg has been 
observed (Huygen, Niehof et al. 2004; Goebel, Vogel et al. 2005; Goebel, 
Baranowski et al. 2010). Recently, we reported that both pain and autonomic 
disturbances ameliorated after plasmapheresis (Blaes, Tschernatsch et al. 
Manuscript under peer-review).  
1.2. Autoimmunity 
The immune system is the body’s natural guardian against disease. It basically 
defends our body from invading pathogenic organisms like bacteria, parasites and 
viruses. It displays several remarkable characteristics which include distinction 
between “self” and “non-self”, and has the ability to remember previous 
experiences (Goldsby, Kindt et al. 2000; Janeway, Travers et al. 2001). The 
concept of autoimmunity was first predicted by Nobel Laureate Paul Ehrlich. He 
described it as ‘horror autotoxicus’. His experiments led him to conclude that the 
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immune system is normally focused on responding to foreign materials and has an 
inbuilt tendency to avoid attacking self-tissues. But when this process goes wrong, 
the result is an inappropriate response of the immune system against self-
components resulting in autoimmune disease. An autoimmune disease can be 
either organ-specific or systemic.  
In an organ-specific autoimmune disease, the immune response is directed to a 
target antigen unique to a single organ or gland, so that the manifestations are 
largely limited to that organ. The cells of the target organs may be damaged 
directly by humoral or cell-mediated effector mechanisms. Alternatively, the 
antibodies may overstimulate or block the normal function of the target organ. 
Some examples of this type of autoimmune disease are Hashimoto’s thyroiditis, 
Goodpasture’s syndrome, Insulin-dependent diabetes mellitus, which are mediated 
by direct cellular damage; and, others are Graves’ disease, Myasthenia gravis, 
which are mediated by stimulating or blocking autoantibodies (Besinger, Toyka et 
al. 1983; Bach 1994; Drachman 1994). 
In systemic autoimmune diseases, the response is directed towards a broad range 
of target antigens, and involves a number of organs and tissues. These diseases 
reflect a general defect in immune regulation that results in hyperactive T and B 
cells. Tissue damage is widespread, both from cell-mediated immune responses 
and from direct cellular damage caused by autoantibodies or by accumulation of 
immune complexes (Klinman 1989; Lin, Mamula et al. 1991). Myasthenia gravis 
usually presented in young adult or later adult life as muscle weakness and 
excessive fatigue during repetitive movements is one example. It often involves the 
extraocular muscles of the eye with double vision and ptosis at onset, but usually 
progresses to a generalized weakness. It is the prototype autoimmune disease 
mediated by pathogenic antibodies. These autoantibodies are directed against the 
nicotinic acetylcholine receptor (nAChR) on the neuromuscular junction or helper 
proteins of the receptor such as the muscle-specific kinase MUSK (Vincent and 
Newsom-Davis 1985; McConville, Farrugia et al. 2004). Interestingly, the anti-
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nAChR antibodies do not block the receptor directly, but lead to a cross-linking of 
receptor molecules and an internalization of the receptor-antibody complexes 
(Elias, Butler et al. 1978; Appel, Elias et al. 1979). 
1.2.1. Mechanism of autoimmunity 
Autoimmunity is not set off by a single cause. The molecular and cellular 
mechanisms of autoimmune responses and their origins are numerous and varied; 
and, even if a given autoimmune disease was initiated primarily by a single trigger, 
many other events and regulating mechanisms come into play thereby adding 
complexity to the process. Autoimmune diseases result from interaction of genetic, 
immune, hormonal and environmental components (Ermann and Fathman 2001). 
For a specific autoimmune condition to develop, a particular combination of these 
factors is required. 
1.2.1.1. MHC control and genetic background  
Genetic markers were delineated, involving specific chromosomal aberration and 
specific genes. Predisposition to a given autoimmune response requires the 
requisite allele(s) that controls antigen presentation by antigen-presenting cells for 
T cell recognition. A striking characteristic of human autoimmune diseases is the 
increased frequency of certain HLA class II alleles in affected individuals. Since 
alleles positively associated with autoimmune diseases share amino acid residues 
in the hypervariable HLA regions involved in peptide binding, it is likely that disease 
associated class II molecules have the capacity to bind the autoantigen and 
present it to T cells, thereby inducing and maintaining the autoimmune disease 
(Adorini 1992; Shoenfeld, Gilburd et al. 2008). For instance, in celiac disease the 
antigluten T cell response is strongly associated with histocompatibility antigen 
HLA-DQ2.5 homozygosity (Fallang, Bergseng et al. 2009; Pietzak, Schofield et al. 
2009).  
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1.2.1.2. Disruption in the level or activity of regulatory proteins and cells 
Immune disturbances can occur because of disruption in the levels or activity of 
regulatory proteins, and consequently regulatory cells. An abnormal T cell or B cell 
activation and cell death signaling underline the pathology of systemic lupus 
erythematosus (Kyttaris, Juang et al. 2005). Moreover, in lupus, B cells exhibit 
abnormal signaling through the B-cell receptor (Jenks and Sanz 2009).  The crucial 
role of regulatory cells in self-tolerance and autoimmunity has been clearly 
established in numerous types of regulatory cells, the majority of which are CD4+ T 
cells. Much focus has been placed on thymus derived CD4+CD25+ regulatory T 
cells, given that the depletion of this subset in murine models results in the 
spontaneous development of autoimmune diseases (Asano, Toda et al. 1996). 
1.2.1.3. Altered proteins  
Proteins to which the immune system is self-tolerant might, if altered, elicit 
autoimmune responses. Mutation and altered expression of proteins trigger 
autoimmune responses that cross-react with unaltered forms of the protein and 
compromise important feedback inhibitory pathways that downregulate antigen 
receptor signaling (Yu, Mamchak et al. 2003). Posttranslational modifications of 
self-proteins can also affect intracellular signaling and protein recognition by the 
immune system. It generates neo-epitopes from self-proteins that are not subjected 
to immune tolerance; as consequence, leads to overt increase in affinity of MHC or 
T-cell receptor binding, and also affect activity of antigen processing enzymes 
(Anderton 2004). These processes as well as covalent modifications of proteins 
are frequently reported after inflammation. Oxidant species that play a role in acute 
and chronic inflammation are able to modify proteins and generate neo-
autoantigens (Nissim, Winyard et al. 2005). Denatured, misfolded or disordered 
proteins have been shown to trigger autoimmune response in similar manner 
(Bouvet and Zouali 2005). 
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1.2.1.4. Apoptosis and autoimmunity to sequestered proteins 
Dysregulated apoptosis, both interrupted as well as accelerated apoptosis, have 
been suggested as central defects in diverse autoimmune disease. Apoptosis 
results in release of cell components that are ordinarily sheltered from the immune 
system, and can be a significant trigger of autoimmunity (Wucherpfennig 1994; 
Zandman-Goddard and Blank 2002). Autoantigens targeted in systemic 
autoimmune diseases share little in terms of structure, subcellular distribution or 
function in normal cells. These molecules are unified by becoming clustered and 
concentrated in the surface blebs of apoptotic cells. Their structure is altered 
during some types of cell death to generate structures not previously generated 
during development and homeostasis (Rosen and Casciola-Rosen 2004). On the 
other hand, apoptosis is essential for the prevention of immunity against self-
antigens, since it enables the disposal of reactive T cells, homeostasis and 
downregulation of autoimmune responses. Abnormal clearance mechanisms can 
allow the persistence of antigenic stimulation; for instance, immune responses that 
specifically target apoptotically modified form of lupus autoantigen have been 
identified in lupus patients (Greidinger 2001). An abnormal  B or T cell apoptosis 
seems nevertheless to play an important role since impaired clearance of apoptotic 
cardiomyocytes, in infants born to mothers with Systemic Lupus erythematosus or 
Sjögren’s syndrome, has been linked to anti-SSA/Ro and –SSB/La antibodies in 
the pathogenesis of congenital heart block (Clancy, Neufing et al. 2006). 
Defect or deficiency in subunits of the proteasome pathway leads to reduced poly-
ubiquitination of altered proteins. Proteolytic processing required for production and 
activation of NF-kB is also impaired in the presence of defective proteosomes. 
Such defect has been suggested to play an important role in immune and 
inflammatory responses, as it increases susceptibility of the affected cells to 
apoptosis induced by TNF-α (Hayashi and Faustman 2000). 
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1.2.1.5. Molecular mimicry 
A major trigger of autoimmune responses and diseases has been shown to 
originate from immune responses to antigens on human-infecting microbes (Sfriso, 
Ghirardello et al. 2010). An autoimmune disease can be induced or triggered by 
infectious agents, whose protein(s) possess homology or structural similarities in 
some of its determinants to regions on proteins of the host; however, they differ 
sufficiently to induce an immune response when presented to T cells. Thus, the 
tolerance to autoantigens can breakdown, and antibodies evoked against a 
pathogen might cross-react with self-proteins and act as autoantibodies. The 
involved autoantigen then provides a source for persistent stimulation (Blank, 
Barzilai et al. 2007).  
In Guillain-Barré syndrome antigenic epitopes are shared between Campylobacter 
jejuni glycoproteins and structures of the myelin sheath (Albert and Inman 1999; 
Goodyear, O'Hanlon et al. 1999). Although the triggering event in most 
autoimmune diseases is unknown, an infectious cause has long been postulated to 
explain the development of many autoimmunities. It is possible that more than one 
pathogen act as a trigger for an autoimmune disease; for instance, scanning of 
protein sequences databases yielded approximately 100 candidate microbial 
determinants regions on different microbial proteins that display similarities to 
autodeterminant epitopes of human acetylcholine receptor, and many displayed 
the ability to bind autoantibodies in sera of myasthenia gravis patients (Deitiker, 
Ashizawa et al. 2000).  
1.2.1.6. Natural antibodies and autoantibodies 
Immunoglobulins that arise independently of known and/or deliberate immunization 
have been termed as natural antibodies. Wide-ranging natural antibodies were 
found to react with self-molecules, and therefore are defined as autoantibodies 
(Atassi and Casali 2008). Natural autoantibodies possess in general a low intrinsic 
affinity for antigens, but can function as templates for the generation of pathogenic 
autoantibodies, that emerge through a process of clonal selection. When self-
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tolerance is disturbed as a result of inflammatory processes, exposure to 
chemicals, molecular mimicry with pathogens, vaccination, receptor editing, 
radiation or genetic background, it can be followed by exposition of autoantigens 
and/or dysregulation of the immune system resulting in the emergence of an 
autoimmune disease. Elevated autoantibody titers will be detected, followed by 
autoantibody spread. Nevertheless, many antibodies can be detected already in 
the pre-clinical phase of autoimmune diseases. The detection of serum 
autoantibodies serve as biomarker for different autoimmune disease diagnostic 
and activity, for the classification and prognosis; and more recently, emerged as a 
predictive tool for development of autoimmunity (Shoenfeld, Blank et al. 2008). 
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II - AIM 
CRPS remains one of the most enigmatic and difficult to treat of all pain conditions, 
probably in large part due to the fact that the pathophysiology remains poorly 
characterized. Recent evidence has begun to focus research on the involvement of 
the immune system in CRPS pathogenesis. Our group showed in a previous report 
that CRPS patients have autoantibodies against nervous system structures. 
Putative autoantibodies have not yet been characterized. Therefore, the aim of this 
study was: 
1. to screen for autoantibodies against surface epitopes of differentiated 
autonomic neurons in CRPS patients, 
2. to identify and characterize autoantibodies using different autoantibody 
detection methods and pharmacological approaches,  
3. to identify target autoantigens and  
4. to assess the functional activity of autoantibodies. 
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III – MATERIALS AND METHODS 
3.1. Patients  
Serum was obtained from patients with clinically defined CRPS, according to the 
revised IASP diagnostic criteria (Bruehl, Harden et al. 1999; Harden, Bruehl et al. 
2007) after informed consent and approval of the local ethical committee (JLU 
Giessen, No 105/02; Landesärztekammer Rheinland Pfalz, No 4208). Sera of 
healthy controls (HC), patients with non-inflammatory neuropathy (NP) and 
patients with peripheral nerve lesions (NL) served as controls. The control groups 
were age- and sex-matched with patients group. Detailed description of patient 
samples are given in result section. For some experiments, we randomly selected 
some serum samples and isolated IgG using affinity chromatography, as described 
below.  
3.2. Materials 
3.2.1. Chemicals and solutions 
Table 1. General laboratory chemicals 
Acetic Acid 100% Merck 
Agarose multipurpose Bioline GmbH 
Ammoniumpersulfat APS Roth 
all-trans retinoic acid Sigma Aldrich 
Atropine Sigma Aldrich 
5-bromo 4-chloro 3-indolyl phosphate / nitro-blue 
tetrazolium chloride (BCIP/NBT)-Blue Liquid 
Substrate 
Sigma Aldrich 
BDH crystalline trypsin (bovine pancreas) Sigma Aldrich 
Bisoprolol hemifumarate salt Sigma Aldrich 
Bovine serum albumine, fraction V (BSA)  Sigma Aldrich 
BQ-610 EMD4 biosciences 
Bromphenolblue Neolab 
Carbamoylcholine chloride Sigma Aldrich 
Carbonate-bicarbonate buffer  Sigma Aldrich 
CelLyticTM M cell lysis reagent Sigma Aldrich 
Clenbuterol hydrochloride Sigma Aldrich 
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Collagenase Worthington type CLS II Biochrom 
Deoxiribunuclease 1, Type 4 bovine pancreas Sigma Aldrich 
Destilled water „Aqua ad injectabilia“ Braun 
D(+)Glucose Gibco 
Dimethylsulfoxide (DMSO) Roth 
Ethylendiamintetracetic acid (EDTA) 0,5M  Roth 
Ethanol 100 %             Sigma Aldrich 
Ethanol for molecular biology 100%  Merck 
Ethidiumbromid  Merck 
Ficoll-PaqueTM Plus Amersham 
Fura-2-acetoxymethylester (fura-2/AM) Invitrogen 
5-Fluoro-2´-deoxyuridine Merck 
Glycerol Roth 
Glycin Merck 
H-EBSS Gibco 
Hepes Sigma 
ICI 118,551 hydrochloride Sigma Aldrich 
IgG-Standard Sigma 
Isopropanol Merck 
Potassiumchlorid (KCl) Merck 
Potassiumdihydrogenphosphat (KH2PO4) Merck 
Methanol Merck 
Magnesiumsulphate (MgSO4) Sigma 
Sodiumchloride (NaCl) Roth 
Sodiumhydrogencarbonate (NaHCO3) Merck 
Disodiumhydrogenphosphate (Na2HPO4) Merck 
Sodiumdihydrogenphoaphate (NaH2PO4) Merck 
Sodiumazide (NaN3) Merck 
Paraformaldehyde (PFA) Sigma Aldrich 
Pluronic acid Invitrogen 
Poly-L-lysin-hydrobromide  Sigma 
Propranolol hydrochloride Sigma Aldrich 
Protein G-sepharose  GE Healthcare  
Quick load 1kb DNA ladder Biolabs 
Recombinant human BMP-2 Biovision 
RNAse free water Fermentas GmBH 
Rotiphorese gel 30 = 30 % Acrylamide-mix Applichem 
Saponin Invitrogen 
TMB peroxidase substrate  KPL 
Transforming growth factor-ß1 Sigma 
Tris-acetat-EDTA buffer (TAE) 10x Neolab 
Trichlor-acetic acid (20%) Roth 
Trishydroxymethylaminomethan (Tris) Roth 
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Tris-HCl  Sigma 
Trypanblue USB 
Trypsin (2,5g/l)  Roth 
5% Trypsin-EDTA (10x) Gibco 
Trypsin inhibitor Type I-S: from Soybean Gibco 
Trypsin Type III-S and XII-S Sigma Aldrich 
Tween20 Sigma Aldrich 
3.2.2. Consumables 
Table 2. General laboratory consumables 
Cellstar® 6 Well Cell Culture Plate Greiner bio-one 
Cellstar® Plastikpipettes (5 ml, 10 ml) Greiner bio-one 
Cellstar® U-shape with Lid, TC-Plate, 96 well, 
sterile           
Greiner Bio-one 
Cellstar®  75 cm2 Cell cultur flasks Greiner Bio-one 
Cell scrapper Greiner bio-one 
Cryobox 136x136x130 mm Ratiolab GmbH 
Cryo TubeTM vials (1,8 mL; 4,5 mL) Nunc 
Disposable scalpel, sterile Feather safity razorco 
Disposable cuvettes Ratiolab 
FACS-Tubes 0,5 mL  38x6,5 mm PS Sarstedt 
Falcon 5 mL Polystyrene Round-Bottom Tube Becton Dickinson 
Falcon® Plastic pipettes 25 mL Becton Dickinson Labware 
Falcon tubes (15 und 50 mL) Becton Dickinson 
Gel documentation Thermal Image System FTI-
500 
Fuji Film 
Glas Pasteur pipettes  150 mm Brand 
Glaswares (different sorts) Fisherbrand; IDL; 
Schott&Gen; Simax 
Kodan® Tinktur Forte (alcoholic skin disinfectant) Schülke & Mayr 
LightCycler® Capillaries [20 µL] (for Real time-
PCR) 
Roche 
Minisart single use filter (0,2 µm, 0,45 µm) Biotech 
Neubauer improved  Brand 
Nitra-Tex® powder free  Ansell 
Nitrocellulose membrane Biometra 
NobaGlove® – Latex powder free NOBA GmbH 
NunclonTM surface 96-Well plates with flat bottom NuncTM 
Parafilm American National Can 
Pipette tipps (10 µL, 100 µL, 1000 µL) Sarstedt 
PP-PCR-Tubes 0,2 mL thin walled Greiner bio-one 
Grid inserts for Cryobox Ratiolab GmbH 
Reaction tubes 1,5 mL Sarstedt 
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Safety-Multifly®–Set, sterile, pyrogenfree 
(Cannulae) 
Sarstedt 
Servapor® dialysis tubing (6mm, 25mm) Serva Electrophoresis 
GmbH 
S-Monovette® 7,5 mL Z (Serum-Tubes) Sarstedt 
Sterile Pipette tips with filter Nerbe Plus 
Tissue culture dishes steril 35,0 / 10 mm  Greiner bio-one 
UV-spectroscopic cuvettes Bio-Rad 
Whatmann-Filterpaper 3 mm  A. Hartenstein 
3.2.3. Instruments 
Table 3. Laboratory instruments 
BEP 2000 Advance (ELISA-Reader) Dade Behring 
Centrifuge typ 2-6 Sigma 
Centrifuge Universal 32 R (cell culture)  Hettich 
ClasII type A/B3 (Sterilbank)  Nuaire Biological Safety 
Cabinets 
Easia shaker Medgenix diagnostics 
FACSCalibur Becoton Dickinson 
Fluorescence microscope DM RB                         Leitz 
Gel documentation image Masters VDS Pharmacia Biotech 
Gel electrophoresis chamber Peqlab 
Gel trays und gel combs Peqlab 
Heating block / Thermoshaker Peqlab 
HiTrapTM protein G HP (1 mL und 5 mL Protein 
G columns) 
Amersham Biosciences 
Inverse light microscope MBL 3100 A.Krüss Optronic 
Inverse fluorescence/Light microscope  Olympus IX-50 
Image analysis system  Till Photonics 
Light Cycler 1.5    Roche Diagnostics 
LightCycler centrifuge adapter Roche Diagnostics 
Liquid nitrogen tank Arpege 75 
Magnetic mixer IKA® Werke 
Microwell SHARP Electronics 
Multiscan Ex (ELISA-Reader) Thermo Electron Corporation
NalgeneTM Cryo 1°C Freezing container Nalgene® 
PC-System, Printer Hewlett Packard 
pH-Meter Schott Geräte 
Pipettes (different volumes) Gilson, Eppendorf 
Pipette boy Integra Biosciences 
Power pack Peqlab 
ProSpec (Nephelometer) Dade Behring 
Pump P-1 (Pump for IgG purification) Pharmacia Biotech 
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Refrigerators and freezers Different companies 
Rotamax 120 (Shaker) Heidolph 
Swivel platform Peqlab 
SmartSpecTM Plus spectrophotometer  Bio-Rad 
Steri-Cult 200 incubator for cell culture Labotec GmbH 
Sterile bench Köttermann 
Thermocycler Biometra 
Table top centrifuge EBA 20 Hettich 
Table top centrifuge micro 120 Hettich 
Universal 32 R (centrifuge) Hettich 
Vortex minishaker IKA® Werke 
Vortexer vortex-Genie2 Scientific Industries 
Weighing balance Sartorius AG 
Waterbath Memmert 
3.2.4. Molecular biology and biochemistry kits 
Table 4. Detection kits 
Cell proliferantion reagent WST-1 Roche Applied Science 
Cytotoxicity detection kit (LDH) Roche Applied Science 
QIAamp® RNA Blood Mini kit Qiagen 
Quanti FastTM SYBR Green PCR kit Qiagen 
RevertAidTM First Strand cDNA Synthesis kit Fermentas 
RNeasy Mini kit  Qiagen 
3.2.5. Buffers and solutions 
Table 5. General buffer and solutions 
DNA-loading buffer (10x) 250 mg 
33 mL  
60 mL 
7 mL 
Bromphenolblue 
Tris (150 mM, pH 7.6) 
Glycerol  
H2O 
Ethidium bromide staining 
solution 
2.5 mg 
1 L 
Ethidiumbromide 
1x TAE                  
FACS buffer 500 mL 
5 mL 
5 mL 
1x PBS  
10 % NaN3 
Fetal calf serum (FCS) 
Glycine buffer 3.75 g 
In 500 mL 
Glycine 
dH2O  
pH  9.0 
IgG-Elution buffer 0.75 g 
100 mL 
 
Glycine 
dH2O 
pH 2.7 (= 0.1 M) 
Blocking buffer 0.5 g 
10 mL 
BSA 
PBS Tween 
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1 % Paraformaldehyde (PFA) 1 g 
100 mL 
PFA 
1x PBS 
PBS (10x) 
 
 
80 g 
2 g 
14.4 g 
2.4 g 
Dissolve in 1 L 
NaCl 
KCl 
Na2HPO4 
KH2PO4 
dH2O  
1x PBS 900 ml 
100 mL 
dH2O 
PBS (10x) 
PBS Tween 1 L 
100 µL 
1x PBS 
Tween 20  
Permeabilisation buffer 500 mL 
0.5 g 
FACS buffer 
Saponin 
Poly-L-lysin 60 mL 
3 mg 
dH2O  
Poly-L-Lysin 
Ponceau S-solution 0.25 g 
15 mL Make 
up 100 mL 
Ponceau S 
Trichloracetate (TCA) 
with H2O (protect from light) 
TBS-buffer 4.5 g 
0.71 g 
0.15 g 
5.5 g 
2.5 mL 
500 mL 
NaCl 
Na2HPO4 
NaH2PO4 
Non fat dry milk 
Tween 20 
dH2O 
Trypsin-solution 10 mL 
2.5 mg 
Solution 1H 
Trypsin 
Trypsin inhibitor solution 10 mL 
1.6 mL 
Solution 1H 
Konz. D/T-I Lsg 
3.2.6. Media and solutions for cell culture 
Table 6. Cell culture media 
HEK 293 RPMI1640 10 % 
2mM 
1 % 
Fetal calf serum (FCS) 
Glutamin (200 mM) 
PenStrep (Penicillin/ 
Streptomycin) 
Gibco 
Hyclone 
Gibco 
Gibco 
SH-SY5Y RPMI1640 10 % 
2mM 
1 % 
Fetal calf serum (FCS) 
Glutamin (200 mM) 
PenStrep (Penicillin/ 
Streptomycin) 
Gibco 
Hyclone 
Gibco 
Gibco 
SN 
 
MEM 10 % 
2mM 
1 % 
Fetal calf serum (FCS) 
Glutamin (200 mM) 
PenStrep (Penicillin/ 
Streptomycin) 
Gibco 
Hyclone 
Gibco 
Gibco 
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MPN DMEM 10 % 
2mM 
1 % 
Fetal calf serum (FCS) 
Glutamin (200 mM) 
PenStrep (Penicillin/ 
Streptomycin) 
Gibco 
Hyclone 
Gibco 
Gibco 
Cardiomyocytes Halle Sm 20-I 10 % 
2 µmol/L
Fetal calf serum (FCS) 
Fluorodeoxyuridine 
Gibco 
Merck 
CHO WT DMEM/HAMs 
F-12 
10 % 
2mM 
1 % 
Fetal calf serum (FCS) 
Glutamin (200 mM) 
PenStrep (Penicillin/ 
Streptomycin) 
Gibco 
Hyclone 
Gibco 
Gibco 
CHO- hβ1AR 
        - hβ2AR 
        - hM2R 
DMEM/HAMs 
F-12 
10 % 
2mM 
1 % 
 
63 mg/L 
Fetal calf serum (FCS) 
Glutamin (200 mM) 
PenStrep (Penicillin/ 
Streptomycin) 
Geneticin 
Gibco 
Hyclone 
Gibco 
Gibco 
Gibco 
3.2.7. Cell lines 
Table 7. Cell lines 
Name Origin Source 
HEK 293  Fibroblast cells  AG Blaes, Neurology - Giessen 
SH-SY5Y Neuroblastoma  AG Blaes, Neurology - Giessen 
CHO-WT Chinese hamster ovary  
kindly provided by Dr. Mohr - Bonn, 
Germany 
CHO-hβ1AR 
Chinese hamster 
ovary, transfected 
with hβ1AR  
kindly provided by Dr. Gerd Wallukat 
- Berlin, Germany 
CHO-hβ2AR 
Chinese hamster 
ovary, transfected 
with hβ2AR 
kindly provided by Dr. Gerd Wallukat 
- Berlin, Germany 
CHO- M2R 
Chinese hamster 
ovary, transfected 
with hM2R 
kindly provided by Dr. Mohr - Bonn, 
Germany 
3.2.8. Antibodies 
Table 8. Primary and secondary antibodies 
Antibodies-Name against raised in Conjugation Company 
Neurofilament human mouse - Dako  
HuD human mouse - Mol. probes 
IgG human rabbit peroxidase Dako 
IgG human rabbit FITC Dako 
IgG mouse rabbit FITC Dako 
IgG rabbit swine FITC Dako 
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IgG 1 human mouse - Sigma 
IgG 2 human mouse - Sigma 
IgG 3 human mouse - Sigma 
IgG 4 human mouse - Sigma 
Isotype-control  mouse FITC R&D Systems 
Isotyp-control  mouse - Dako 
Isotyp-control  rabbit FITC Dako 
M2R human mouse - Santa Cruz 
β2AR human rabbit - Abcam 
 
3.2.9. Primers 
Table 9. Primer sequences 
Description Nucleotide sequence NCBI GenBank 
PBGD 8F fwd 5´-TGCAACGGCGGAAGAAAAC-3´ 
PBGD 3.1 rev 5´-GGCTCCGATGGTGAAGCC-3´ NM_00190 
DßH fwd 5’ - ACTGTCCACTTGGTCTACGGG - 3’ 
DßH rev 5’ - CGGTCGGGTTTCATCTTG - 3’ NM_000787 
VAChT fwd 5’ - GGGGCATCCTCTATGAGTTCG - 3’ 
VAChT rev 5’ - GTGGCAATGGTGGGTTCG - 3’ HSU09210 
M2R fwd 5’ - CCAATGCTGCTGTCACCT - 3’ 
M2R rev 5’ - TTGGCTTCACTATCCTTCCT - 3’ NM_000739 
β2AR fwd 5’ - CTTCTGGTGCGGAGTTTTGGAC - 3’ 
β2AR rev 5’ - AATCTTCTGGAGCTGCCTTTT - 3’ NM_000024 
3.2.10. Software 
BEP® 2000 SW V.1.23.4 (ELISA-Reader) 
CellQuest®  BD (FACSCalibur)  
Excel 2002 Microsoft  
Graph Pad Prism Software Version 4.02 (Statistical analysis + Grafics)  
Microsoft Office PowerPoint 2003  
Microsoft Office Word 2003  
QC-Net (Unity Real Time) Bio Rad (Nephalometer analysis) 
Roche Molecular Biochemicals Light Cycler Software Version 3.5 (LightCycler)  
Windows 2002 Microsoft  
WinMDI 2.9 (analysis of FACS data)  
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3.3. Methods 
3.3.1. Experiment set 1: Autoantibody detection by flow cytometry 
on the surface of differentiated autonomic cells 
For this group of experiment, serum samples of controls, CRPS patients or 
PNP/NL were tested in non-neuronal cells, autonomic primary neurons, 
undifferentiated and autonomic differentiated neuroblastoma cells for surface 
binding using basically flow cytometry (FACS). Isolation of neurons from rats were 
approved by the local ethical committee and followed International Guidelines for 
the Care of Research Animals. 
3.3.1.1. Cell culture  
The neuroblastoma cell line SH-SY5Y, which originates from a tumour of the 
sympathetic nervous system, were cultured in RPMI 1640 medium containing 10% 
heat-inactivated fetal calf serum, 2 mM L-glutamine, 1% penicillin, 1% 
streptomycin. The cultures were maintained in a 37°C humidified atmosphere of 
95% air and 5% CO2. To test for surface autoantibody binding, we used the SH-
SY5Y undifferentiated or differentiated according to the protocol given below. The 
epithelial cell line HEK 293 cultured in the same conditions served as a non-
neuronal control cell line. We additionally tested primary cultures of sympathetic 
neurons and gut myenteric plexus neurons from rats isolated and cultured as 
described below. The experiment was approved by the local ethical committee and 
followed International Guidelines for the Care of Research Animals. 
3.3.1.2. Differentiation of neuroblastoma cells 
For differentiation experiments, SH-SY5Y cells were plated at 20,000 cells/cm2 and 
cultured for 2 days prior to differentiation. Cells were differentiated by incubation 
with the following agents for 4 days: all-trans retinoic acid at 10 µM; BMP-2  at 10 
ng/mL; transforming growth factor (TGF)-β1 at 10 ng/mL. We also used 
combinations of RA and BMP-2 or RA and TGF-β1 under the same conditions. 
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3.3.1.3. Isolation of sympathetic neurons 
Adult Wistar rats were anaesthetised with halothane and sacrificed by cervical 
dislocation. The whole vertebral column was then removed and the sympathetic 
trunk on either side was dissected over its full length including cervical and lumbar 
ganglia. All ganglia were cut out of the trunk, cleaned from connective tissue and 
placed into calcium- and magnesium-free phosphate-buffered saline (PBS). The 
ganglia were incubated in 6 mg/mL collagenase Worthington type CLS II and 2 
mg/mL trypsin type III-S for 40 min in a shaking water bath at 37°C. Afterwards, the 
ganglia were washed three times with plating medium (minimum essential medium 
(MEM) supplemented with 10% fetal calf serum, 1% penicillin / streptomycin and 
1% glutamine). Cells were then dissociated by repeated passages through three 
Pasteur pipettes with decreasing diameter, and then stored in plating medium 
under a humidified 5% CO2 atmosphere at 37°C. 
3.3.1.4. Isolation of gut myenteric plexus 
As described previously in (Schafer, Klotz et al. 2000), myenteric plexus from 12- 
or 13-day-old Wistar rats was obtained. After decapitation the whole gut was 
removed and stored on ice-cold MEM eagle. In the small intestine the smooth 
muscle layer was separated from the submucosal layer under microscopic control 
at 15x magnification. The colon was flushed, opened and incubated as a whole in 1 
mL of a Collagenase solution (Worthington CLS II, 1 mg per mL in : Hank’s 
balanced salt solution) at 37°C for 1.5 h. After the digestion step the vials were 
mechanically agitated using a vortex. The already visible plexus pieces were 
collected and transferred into another petri dish with ice-cold MEM. The remaining 
undigested tissue was re-digested with a fresh collagenase solution at 37°C for 
another 15 min. The procedure was repeated again until muscle pieces were 
digested. Finally, the plexus pieces were collected and centrifuged at 1000 rpm for 
2 min. The supernatant was decanted and the pellet was incubated with 1 mL 
trypsin for 5 min. After centrifugation at 1000 rpm for 10 min, the trypsin solution 
was replaced by Dulbecco’s Modified Essential Medium (DMEM) containing 10% 
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fetal calf serum (FCS), 1% penicillin / streptomycin and 1% glutamine. Then the 
plexus was dissociated by aspirating through a 27-gauge needle. 
3.3.1.5. Autoantibody detection by flow cytometry 
We introduced flow cytometry (FACS) to detect autoantibodies in 
neuroimmunological diseases (Blaes, Beeson et al. 2000). To avoid unspecific 
binding to ubiquitous antigens, we pre-absorbed the sera by incubating in PBS 
containing 1% FCS and 0.1% NaN3 (FACS buffer) with HEK 293 cells for 24 h at 
4oC (serum dilution 1/50) prior to incubation of the primary cell cultures. The 
different cell lines and primary cultures described above were then incubated with 
the pre-absorbed HC, CRPS or PNP/NL patients’ sera for 30 min at 4oC, washed, 
and incubated again with FITC-conjugated anti-human IgG (30 min, 4oC in dark). 
After washing again, binding was analyzed in a FACScalibur using CellQuest® 
software. After measurement of the mean fluorescence intensity (MFI), the mean 
MFI of the controls of each experiment has been set as 100%. For each serum, the 
percentage of difference from the controls was calculated. This standardization is 
necessary since the binding, given as MFI, of patients sera to a mixed primary cell 
culture can vary between the experiments. A percentage above mean + 2.5 
standard deviations of the controls was considered positive. To avoid irrelevant 
binding to intracellular antigens, we tested the primary cell cultures with trypan blue 
for viability and also measured binding of anti-neurofilament antibody to non-
permeabilized cells.  
3.3.1.6. Identification of neuronal cells  
To show neuronal specific-binding, cells were incubated with the patients sera and 
FITC-conjugated anti-human IgG as described above, fixed with 2% 
paraformaldehyde (20 min, 4oC), permeabilized with FACS-buffer containing 0.1% 
saponine and then incubated with the neuronal-specific anti-HuD antibody. Cells 
were than gated according to their reactivity to the neuronal anti-HuD protein and 
only positive (neuronal) cells were analyzed in flow cytometry.  
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3.3.1.7. PCR experiments 
Total RNA was isolated using RNeasy Mini Kit as per manufacturer's instructions. 
RNA quantity was determined with a BioRad spectrophotometer. Total RNA (1 µg) 
was subjected to reverse transcription using Oligo(dT)18 Primer. The RNA/primer 
mixture was denatured at 70°C for 5 min before the addition of a MasterMix 
containing 1 µL RiboLock™ RNase Inhibitor (20 u/µL), 2 µL of 10 mM dNTP mix, 4 
µL 5× Reaction buffer and 1 µL RevertAid™ M-MuLV Reverse Transcriptase (200 
u/µL) in diethylpyrocarbonate treated H2O. The reactions were incubated for 60 
min at 42°C before quenching for 10 min at 70°C. cDNA was stored at 4°C until 
further use. Primer sequences used for PCR were designed using Primer Premier 
5® software. Expression of dopamine-β-hydroxylase (DßH) and vesicular 
acetylcholine transporter (VAChT) was assessed by polymerase chain reaction 
(RT-PCR). Primer sequences used are DßH: F: 5’ - 
ACTGTCCACTTGGTCTACGGG - 3’ and R: 5’ - CGGTCGGGTTTCATCTTG - 3’; 
VAChT: F: 5’ - GGGGCATCCTCTATGAGTTCG - 3’ and R: 5’ - 
GTGGCAATGGTGGGTTCG - 3’; and porphobilinogen deaminase (PBGD): F: 5’ - 
TGCAACGGCGGAAGAAAAC - 3’ and R: 5’ - GGCTCCGATGGTGAAGCC - 3’. 
PBGD was used as a housekeeping gene because its level is not affected by the 
differentiation protocol used. Each PCR amplification contained 1 µL cDNA, 2.5 µL 
10x reaction buffer, 1 µL each of forward and reverse primers for gene of interest 
and 0.5 µL Taq polymerase. The reaction was supplemented with nuclease free 
H2O to bring the volume to 25 µL. Thermal cycling conditions used are as follows: 
initial denaturation at 95°C for 5 min, followed by 30 cycles of 95°C for 30 sec, 
58°C for 30s, 72°C for 30 sec and a final extension at 72°C for 5 min. A negative 
template control containing 1 µL nuclease free H2O was included for each set of 
primers. To confirm presence of product and amplicon size, PCR products were 
separated on 1% agarose gel and stained with ethidiumbromide. 
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3.3.2. Experiment set 2: Identification of putative autoantigens 
targeted by CRPS serum antibodies 
In this section, we randomly selected 10 HC, 20 CRPS, 10 PNP/NL patients, no 
matter whether positive or negative in previous experiments, and isolated IgGs. 
Affinity-purified IgGs were tested in a well-established method to detect 
autoantibodies against autonomic receptors, the spontaneously beating neonatal 
rat cardiomyocytes assay (Wallukat and Wollenberger 1987; Wallukat and 
Wollenberger 1991). Further, target protein sequences were identified and re-
tested in an Enzyme immunoassay. 
3.3.2.1. Cell culture  
Chinese hamster ovary (CHO) cells wild-type or overexpressing human muscarinic 
2 receptor (kindly provided by Dr. Mohr - Bonn, Germany),  β1- or β2-adrenergic 
receptor  (kindly provided by Dr. Gerd Wallukat - Berlin, Germany) were cultured in 
DMEM/HAMs F-12 containing 10% fetal bovine serum, 2 mM L-glutamine, 1% 
penicillin and 1% streptomycin. The medium for stable transfected cells was 
enriched additionally with geneticin (63 mg/L) as selection antibiotic. SY5Y 
neuroblastoma cells were cultured and differentiated as described before. 
3.3.2.2. Affinity chromatography 
Serum was diluted 1:3 with glycine buffer (0.1 Mol, pH 9), applied to a protein G-
sepharose column (HiTrap - GE) that binds exclusively IgG, and the rest of the 
serum was washed out using glycin buffer (pH 9). IgG-fractions were eluted by 
changing the pH from 9 to 2.7. The IgG-concentration was determined by 
nephelometry (Boehring). Each IgG-fraction was dialysed against PBS to eliminate 
the glycin and increase the pH up to 7.4 
3.3.2.3. Preparation of cardiomyocyte cultures 
Neonatal rat cardiomyocytes were isolated and cultured as described by Wallukat 
and Wollenberger (Wallukat and Wollenberger 1987). The experiment was 
approved by the local ethical committee and followed International Guidelines for 
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the Care of Research Animals. Hearts were removed aseptically from 1- to 2-day-
old Wistar rats. Single cells were dissociated from the minced heart ventricle with a 
0.25% solution of trypsin. The cardiomyocytes were cultured as monolayers with a 
density of 800 cells/mm2 on the bottom of 45-mL Muller bottles (1.2x 106 seeded 
cells in 3 mL medium) in Halle SM20-I medium containing 10% heat-inactivated 
calf serum and 2 µmol/L fluorodeoxyuridine, the latter to prevent proliferation of 
nonmuscle cells. The flasks were attached to a plate that was continuously rocked 
back and forth at two cycles of 30 each per min to ensure an adequate gas and 
metabolite exchange. After first 24 h of incubation, additional 400 µL of fresh 
medium was added to each flask, and cells were further cultivated for additional 4 
days before the experiments. 
3.3.2.4. Peptides 
Peptides corresponding to the sequence of the second extracellular loop of human 
M2R (residues 169-193): VRTVEDGECYIQFFSNAAVTFGTAI;  and, β2AR 
(residues 172-197): HWYRATHQEAINCYANETCCDDFFTNQ  were synthesized 
by Thermo Fisher Scientific (Ulm, Germany) in short overlapping peptides 
containing 6 to 7 amino acids each, and used as described below in each 
experimental section.  
3.3.2.5. Pharmacological assays 
The flasks containing spontaneously beating cardiomyocytes were transferred to 
the heatable stage of an inverted microscope. The contraction rate of seven to ten 
clusters of synchronously beating cells - in selected ten fields per flask - were 
counted for 15 s, which served as the basal beating rate. This procedure was 
replicated in different culture to yield the results, representing a total of up to 30 
cells or clusters for each sample of given immunoglobulin. The basal beating rate 
was 140 ± 20 beats per min. The compounds to be tested were dissolved in the 
same medium used for the determination of the basal beating rate. 
Cardiomyocytes were incubated with IgG of HC, CRPS, or PNP/NL at a final 
concentration of 60 mg/L. Changes in beating frequency of each selected field 
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were measured 1 h after the addition of IgGs. At this point (without removing the 
previously added IgG), adrenergic/cholinergic agonist/antagonist drugs (carbachol 
10 µM, atropine 1 µM, ICI 118.551 0.3 µM, clenbuterol 3 µM or propranolol 1 µM) 
were applied to the beating cultures and, after five minutes, beating frequencies 
were measured again. Additionally, we tested the effect of a selective β1AR-
antagonist (bisoprolol 1 µM) and endothelin 1 receptor antagonist BQ-610 (1 µM). 
All drugs were obtained from Sigma. 
In different experiments, we preincubated the cardiomyocytes with antagonists - 
propranolol or atropine – to block the β2AR or M2R before adding 
immunoglobulins. This procedure was important to analyze the isolated effect of 
each pathogenic antibodies since they showed opposite effect on cardiomyocytes. 
To map the epitopes in the first, second or third extracellular loops of both 
receptors, immunoglobulins were preincubated with each short sequence of 
overlapping peptides of both receptors for 1 h at 4°C, at a final concentration of 1.5 
g/L of antibody and 10 mg/L of the peptides. IgG/peptide solution was added to 
cardiomyocytes (preincubated either with atropine or propranolol) and beating 
frequencies were then measured after 60 minutes as described above. 
To test whether there is cross reactivity between antibodies that bind β2AR or 
M2R, we preincubated IgG of CRPS patients with sequences of β2AR or M2R 
peptides, and in parallel incubated cardiomyocytes with propranolol (1 µM) or 
atropine (1 µM). The intention was to determine if those antibodies responsible for 
the activation of M2R can be blocked by peptides of the β2AR or vice versa.  
3.3.2.6. Enzyme immunoassay 
NUNC microtiter plates were coated with 50 µg/mL of synthetic peptides 
corresponding to the sequences of the second extracellular loop of both the human 
β2AR and M2R in 100 mM carbonate–bicarbonate buffer (pH 9.6) overnight at 4°C. 
In order to avoid unspecific binding, blocking solution (phosphate buffered saline + 
0.1% Tween 20 – PBST - supplemented with 5% BSA) was added to the wells and 
the plates maintained at room temperature for 1 h. After three washings, affinity-
purified 60 mg/L of immunoglobulins from CRPS patients and HC were allowed 
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to adsorb on the peptides for 2 h at room temperature. After washing the wells 
three times with PBST, bound antibodies were revealed by successive 2 h 
incubation at room temperature with a peroxidase conjugated anti-human IgG 
(diluted 1:6000 in PBST). This was again followed by three washing procedures, 
and then a TMB peroxidase substrate was added. After 7 minutes, 100 µL of 1 N 
HCl were added to stop the reaction. The optical density was measured at 450 nm 
in an ELISA plate reader. 
3.3.3. Experiment set 3: Determination of immunoglobulin 
subclasses of CRPS pathogenic antibodies  
Autoantibodies against the β2AR and the M2R belong to the IgG class. IgG 
includes the subclasses IgG1-4. These subclasses differ immunologically and 
functionally, and the subtype identification of pathogenic antibodies might indicate 
which T helper (Th) cell subset is mostly involved in an autoimmune response, and 
whether autoantibodies may be able to bind complement. Thus, to determine the 
immunoglobulin subclasses of pathogenic antibodies we incubated affinity-purified 
immunoglobulin samples with mouse anti-human IgG1, -2, -3 and -4 antibodies for 
1 h at 4°C, centrifuged and used the supernatant to assess changes in the beating 
rate of heart muscle cells in the same conditions as described above. 
3.3.4. Experiment set 4: CRPS pathogenic antibodies bind to the 
surface of stable transfected cells 
In order to determinate whether CRPS autoantibodies identify autoantigens 
transfected in cells that do not constitutively express them, we performed flow 
cytometry assay using wild type and stable transfected CHO cells. 
3.3.4.1. Antibody binding measured by flow cytometry 
We introduced flow cytometry (FACS) assay to detect autoantibodies in 
Experiment set 1. Binding experiments in this assay have been done using isolated 
IgG fractions instead sera. To avoid unspecific binding to ubiquitous antigens, we 
pre-absorbed the IgGs by incubating them in PBS containing 1% FCS and 0.1% 
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NaN3 (FACS buffer) with wild type CHO cells for 24 h at 4°C (serum dilution 1/50) 
prior to incubation with receptor-transfected cells. Wild type and receptor-
transfected CHO cells were then incubated with the pre-absorbed IgGs for 30 
minutes at 4°C, washed, and incubated again with FITC-conjugated anti-human 
IgG (Dako) (30 minutes, 4°C in dark). After washing again, binding was analyzed in 
a FACScalibur using CellQuest® software. Mean fluorescence intensity above 
mean + 2.5 standard deviations of the controls for each cell line was considered 
positive. To avoid irrelevant binding to intracellular antigens, we tested cell cultures 
with trypan blue for viability and membrane integrity.  
3.3.4.2. PCR experiments 
We checked additionally the expression of β2AR and M2R in SH-SY5Y cell 
differentiated with BMP-2 and/or RA using the method describe above. Primer 
sequences used are β2AR: F: 5’ - CTTCTGGTGCGGAGTTTTGGAC - 3’ and R: 5’ 
- AATCTTCTGGAGCTGCCTTTT - 3’; M2R: F: 5’ - CCAATGCTGCTGTCACCT - 3’ 
and R: 5’ - TTGGCTTCACTATCCTTCCT - 3’; and porphobilinogen deaminase 
(PBGD): F: 5’ - TGCAACGGCGGAAGAAAAC - 3’ and R: 5’ - 
GGCTCCGATGGTGAAGCC - 3’. RNA isolation and PCR conditions were same as 
described in Experiment set 1. The annealing temperature for these primers was 
set at 55°C. 
3.3.5. Experiment set 5: Functional assays 
3.3.5.1. Functional cardiomyocyte assay 
Affinity purified antibodies from CRPS patients were added to the medium of 
spontaneously beating cardiomyocytes - pre-treated either with atropine or 
propranolol - and their effect was investigated as a function of time. IgG-induced 
changes in beating rate were evaluated after 5, 60, 120, 180 and 400 minutes. 
Afterwards, antagonists (0.3 µM ICI 118,551 or 1 µM atropine) were add to the 
solution, after 5 minutes washed out for more 5 minutes, and then the agonists (3 
µM clenbuterol or 10 µM carbachol) were added. 
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3.3.5.2. Receptor expression 
hβ2AR- and hM2R-transfected CHO cells were incubated with HC or CRPS IgGs 
for 24 h and 48 h at 37°C, harvested and incubated with anti- β2AR antibodies 
(Abcam) or anti-M2R antibodies (Santa Cruz Biotechnology). The surface 
expression of receptors was analyzed using flow cytometry as described above. 
The experiment was performed in triplicate. 
3.3.5.3. Calcium imaging 
Relative changes in the intracellular Ca2+ concentration were measured using the 
Ca2+-sensitive fluorescent dye fura-2, as described previously in (Haschke, Schafer 
et al. 2002). The maximum excitation wavelength of fura-2 shifts in dependence of 
the cytoplasmatic Ca2+ concentration. CHO cells (wild type or expressing hβ2AR or 
hM2R) grown on glass slides were loaded for 60 minutes with 5 µmol/L fura-2-
acetoxymethylester (fura-2/AM) in the presence of 0.1 g/L pluronic acid. Fura-2 
was then washed away. Further, glass slides were transferred into the 
experimental chamber with a volume about 1 mL, and then cells were superfused 
hydrostatically with tyrode solution (1 mL/min). The baseline in the fluorescence 
ratio of fura-2 was measured for some minutes before IgG or drugs were 
administered.  
At this point, HC or CRPS IgG were added to the cells at a final concentration of 60 
mg/L, and the effect was recorded for approximately ten minutes. The agonist 
clenbuterol (30 µM) for hβ2AR-CHO and bethanechol (100 µM) for hM2R-CHO 
were added to the cells - without washing the previously added IgG - and changes 
in intracellular Ca2+ concentration were measured for further five minutes. 
Additionally, in another set of experiments, cells were pre-treated with antagonist 
propranolol (10 µM) for hβ2AR-CHO or atropine (10 µM) for hM2R-CHO five 
minutes before addition of IgGs and agonists. Experiments were carried out at 
room temperature on an inverted microscope (Olympus IX-50) equipped with an 
epifluorescence and an image analysis system (Till Photonics). The emission 
above 470 nm was measured from several regions of interest, each with the size of 
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about one cell. The cells were excited alternatively at 340 and 380 nm and the ratio 
of the emission signal at both excitation wavelengths was calculated. Data were 
sampled at 0.33 Hz.  
3.3.6. Experiment set 6: Cytotoxicity of pathogenic autoantibodies 
Here we tested whether surface binding autoantibodies are able to induce 
cytotoxicity in receptor-transfected cells. 
3.3.6.1. LDH 
Cytotoxicity was assessed with a lactate dehydrogenase (LDH)-cytotoxicity 
detection kit, which measures LDH activity released from the cytosol of damaged 
cells. Cells were grown in 96-well culture plates, at 37°C, for 24 h to near 
confluence. Cells grown in 96-well plates were exposed to IgGs (120 mg/L) for 24 
h. After that, 100 µL of supernatant per well was harvested and transferred into a 
new 96-well, flat-bottom plate. LDH substrate (100 µL) was added to each well and 
incubated for 30 minutes at room temperature protected from light. The 
absorbance of the samples was measure at 490 nm with an ELISA reader. 
Cytotoxicity was calculated with the formula: % cytotoxicity = (experimental value - 
low control) x 100/(high control - low control), where low control is assay medium 
plus cells and high control is assay medium (plus 2% Triton X-100) plus cells. 
3.3.6.2. WST-1 assay 
The cell proliferation reagent WST-1 is a water-soluble tetrazolium salt that can be 
used for cell proliferation or cell viability assays. The rate of WST-1 cleavage by 
mitochondrial dehydrogenases correlates with the number of viable cells in the 
culture. This assay is appropriate not only for the measurement of cell proliferation 
and growth inhibition, but also for determination of the cytotoxic effect in response 
to growth factors, cytokines, mitogens or antibodies. CHO cells were plated in 96 
well plates containing 100 µL of DMEM medium and cultured for 2 days prior to the 
stimulation with 120 mg/L IgGs. After 24 h stimulation, WST-1 reagent is added 
directly to the cells (1/10 of the culture volume) and absorbance measured at 450 
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nm using an ELISA plate reader following 1 h, 2 h and 3 h incubation at 37°C in a 
humidified atmosphere.  
3.3.7. Statistical analysis 
Frequency of autoantibodies and comparison with clinical data was analyzed by 
Fisher’s exact test. Surface binding, ELISA optical densities and changes in the 
beating rate or in the fura-2 ratio were in part analyzed by analysis of variance 
(ANOVA) for multiple comparisons followed by Turkey’s test for a posteriori 
comparison of means, or Student’s t-test as appropriated. All parametric tests, 
even those including groups with small sample size (e.g. n < 10), were performed 
after validating the normal distribution of the datasets using the Kolmogorov-
Smirnov test; and, the equal variances using Bartlett’s test. For the remaining data, 
we applied the Kruskal-Wallis H test or Friedman test with post Dunn's multiple 
comparison testing, or Mann Whitney test as appropriated. Unless indicated in the 
figure legend or elsewhere, data were expressed as mean + S.E.M. The degree of 
linear relationship between ELISA optical density values for different peptides was 
tested by Pearson’s correlation since all data showed normal distribution; and, 
between ELISA optical density values for different peptides, changes in the beating 
rate or the presence of surface binding antibodies and clinical data of CRPS 
patients were tested by Spearman’s correlation. All statistical analyzes were 
performed using Prism® 4.02 Software (Graph Pad Inc.). The probability level 
accepted for significance was p < 0.05. 
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IV – RESULTS 
4.1. Experiment set 1: Serum autoantibodies in complex regional 
pain syndrome bind to a differentiation-dependent neuronal 
surface-autoantigen 
4.1.1. Patients 
Serum was obtained from 30 patients with clinically defined CRPS (20 CRPS 1, 10 
CRPS 2, according to the revised IASP diagnostic criteria (Harden, Bruehl et al. 
2007); mean age 48.5 ± 11.8 years; 19 female, 11 male). Sera of 30 HC, 20 NP 
(10 diabetes type II, 5 hereditary sensorimotor neuropathy, 5 alcoholic neuropathy) 
and 20 NL patients (6 carpal tunnel syndrome, 6 radial nerve lesion after upper 
arm fracture, 4 patients with idiopathic plexus neuritis, 4 pressure palsy of the 
peronaeal nerve) served as controls. The control groups were age- and sex-
matched (HC 52.6 ± 12.4 years, NP 58.4 ± 14.0, NL 54.5 ± 17.4). None of the 
healthy controls or NL and 11/20 NP patients had a history of chronic neuropathic 
pain. The mean duration of CRPS symptoms in our patients’ group was 25.1 ± 23.8 
weeks and 287.4 ± 155.5 weeks for the NP group. The clinical and epidemiological 
data of the CRPS patients are given in Table 10. Twelve of the CRPS patients 
have been described elsewhere (Blaes, Schmitz et al. 2004). 
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Table 10. Clinical and epidemiological data of the CRPS patients.  
__________________________________________________________________
Age     52.8 ± 13.8 
Sex     25 f / 15m 
CRPS 1 / CRPS 2   20 / 10 
Affected limb (upper / lower)  24 / 6    
Surgery    17/30 
Motor impairment   21/30 
Sensory impairment   20/30 
Trophic changes   24/30 
Time to serum analysis1 (weeks) 25.1 ± 23.8 
1time between onset of symptoms and obtaining of serum 
4.1.2. Surface binding to primary cultured autonomic neurons 
Both primary cultures (SN and MPN) showed a high purity for neuronal cells (70.1 
– 88.5 % neurons in sympathetic neuronal culture and 68.7 – 83.3 % neurons in 
myenteric plexus culture). Sera have been tested for surface binding to 
sympathetic neurons (SN) and myenteric plexus neurons (MPN). Only binding to 
neuronal cells identified by anti-HuD antibody was considered positive. Flow 
cytometry analysis (Figure 4A) revealed autoantibody binding to SN or MPN in 
13/30 (43.3%) of the CRPS patients, but only in 1/20 NP patients, 1/20 NL patients 
and none of the healthy controls (one-way ANOVA, p < 0.0001). Nine patients 
showed binding to both SN and MPN, sera of two patients bound exclusively to 
SM, but not to MPN, and two CRPS sera contained autoantibodies against MPN, 
but not SN (shown for binding to SN, Figure 4B).  
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Figure 4. Surface-binding antibodies detected by flow cytometry using sympathetic neurons. (A) 
Binding of a CRPS serum (filled graph) and a control serum (line graph) to sympathetic neurons. (B) 
Binding to sympathetic neurons (expressed as percent difference to the mean binding of the 
controls) after pre-incubation of the sera with HEK 293 cells to remove unspecific binding. Cut-off, 
marked as horizontal line, was determined as mean of the controls + 2.5x std dev. CRPS patients 
have more and higher binding to SN than controls, neuropathy patients (NP) or peripheral nerve 
lesions patients (NL).   
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4.1.3. Binding to undifferentiated SH-SY5Y neuroblastoma cells  
Only 20% (6/30) of the CRPS patients, one of the NP patients and none of the 
other control groups showed binding to undifferentiated SH-SY5Y neuroblastoma 
cells (one-way ANOVA, p < 0.01, Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Binding of CRPS and control sera to undifferentiated SH-SY5Y cells measured by flow 
cytometry. ANOVA, p < 0.01. Cut-off, marked as horizontal line, was determined as mean of the 
controls + 2.5x std dev.  
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4.1.4. Binding to differentiated SH-SY5Y neuroblastoma cells 
Binding to primary cultured (and well-differentiated) autonomic neurons was 
detectable in more than twice the patients compared to undifferentiated SH-SY5Y. 
Therefore we differentiated SH-SY5Y neuroblastoma cells into different neuronal 
phenotypes to test whether the recognized antigen is differentiation-dependent or 
not. We used a variety of differentiation agents (RA, TGF-β1, TGF-β1/RA, BMP-2 
or BMP-2/RA) and checked the differentiated neurons for cholinergic and 
catecholaminergic markers. Dopamine-β-hydroxylase was induced by 
differentiation with TGF-β1, but strongly downregulated by BMP-2/RA 
differentiation (Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. PCR characterization of differentiated SH-SY5Y cells. Different agents induce 
differentiation of SH-SY5Y cells into two different neuronal phenotype. SH-SY5Y cells were 
differentiated using TGF-β1, RA, BMP-2 alone or in combinations. After differentiation total RNA 
was prepared and subjected to cDNA synthesis. This cDNA was used for PCR amplification of 
VAChT, DβH and PBGD.  
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In contrast, the cholinergic marker vesicular acetylcholine transporter (VAChT) was 
downregulated using TGF-β1 and slightly upregulated by RA and BMP-2/RA 
differentiation. This indicates that TGF-β1 induces a more catecholaminergic 
neuronal phenotype, whereas BMP-2/RA induces a cholinergic neuronal 
phenotype. Then CRPS and control groups were incubated with the differentiated 
neurons to detect specific surface-binding. CRPS and controls did not show 
significant binding to either TGF-β1-differentiated, RA-differentiated or BMP-2-
differentiated SH-SY5Y cells (Figure 7A-C). There was even a tendency to a lower 
binding of the CRPS sera to the TGF-β1- and the TGF-β1/RA-differentiated cells 
(Figure 7B,C). However, if SH-SY5Y cells are differentiated with a combination of 
RA and BMP-2 - inducing a cholinergic neuronal phenotype, 60.0% (18/30) of 
CRPS sera, but only one of the NL patients and none of the other control patients 
showed any significant surface-binding (one-way ANOVA, p < 0.001, Figure 7D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 48
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Surface binding of autoantibodies to differentiated SH-SY5Y neuroblastoma cells. SH-
SY5Y cells differentiated with (A) RA, (B) TGF-β1, (C) TGF-β1/RA, or (D) BMP-2/RA were 
incubated with CRPS and control sera and their binding was analyzed by flow cytometry. Only 
BMB-2/RA-differentiated cells express a surface autoantigen recognized by CRPS sera. (A-C) 
ANOVA, p > 0.05. (D) ANOVA, p < 0.001. RA = Retinoic acid; TGF-β1 = Transforming growth factor 
beta 1; BMP-2 = Bone morphogenic protein-2. 
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4.1.5. Association with clinical data 
We compared surface-binding in CRPS with clinical and epidemiological data. 
Patients with and without surface-binding autoantibodies to primary cultured 
autonomic neurons or differentiated cells did not differ in any epidemiological or 
clinical features tested (Table 11). 
 
 
Table 11. Clinical data of surface-binding positive and negative patients. 
Feature        Surface-binding (+)        Surface-binding (-)      p 
     (n = 13)              (n = 17)    
Age      52.5 ± 15.6  50.6 ± 10.8  n.s. 
Sex     8f / 5m   11f / 6m  n.s. 
CRPS type      6 CRPS 1   14 CRPS 1  n.s. 
     7 CRPS 2  3 CRPS 2 
Affected limb    12 upper /   12 upper /   n.s. 
     1 lower   5 lower 
Operation    6/13   11/17   n.s. 
Motor impairment1   8/13   13/17   n.s. 
Sensory impairment2   8/13   12/17   n.s. 
Skin Temperature3   7/10*   10/16*   n.s. 
Hair growth3    5/10*   6/16*   n.s. 
Sweating abnormalities3  4/10*   8/16*   n.s. 
Time to serum analysis4 (weeks) 37.6 ± 35.3  20.9 ± 19.2  n.s. 
Fisher’s exact test, p > 0.05. 1any paresis in the affected limb, not related to nerve lesion; 2any sensory disturbances, not 
related to nerve lesion;  3increased or decreased; 4time between onset of symptoms and obtaining of serum;  *information 
not available from all patients 
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4.2. Experiment set 2: CRPS immunoglobulins bind to the surface 
of cardiomyocytes on the M2R and β2AR 
4.2.1. Patients 
Serum was obtained from 20 clinically diagnosed CRPS patients, according to the 
IASP diagnostic criteria (Harden, Bruehl et al. 2007) (10 CRPS 1, 10 CRPS 2; 
mean age 48.5 ± 13.8 years; 12 female, 8 male), who all had autonomic symptoms 
such as sweating abnormalities or vasomotor changes on the affected limb. Sera 
of 10 HC, 9 patients with NP (n = 4) or NL (n = 5) served as age- and sex-matched 
controls. None of the HC, but 4/9 PNP/NL patients had a history of chronic 
neuropathic pain. The clinical and epidemiological data of the CRPS patients are 
given in Table 12. 
 
Table 12. Clinical and epidemiological data of the CRPS patients.  
Age    48.5 ± 13.8 
Sex    12 f / 8 m 
CRPS 1  / CRPS 2  10 / 10 
Warm / Cold CRPS  15 / 5 
Pain Score (Median)  4 (25% Percentile = 0, 75% Percentile = 7) 
Affected limb (upper / lower) 18 / 2    
Surgery   12/20 
Trauma   11/20 
Motor impairment1  14/20 
Sensory impairment2  10/20 
Trophic changes  11/20 
Time to serum analysis3 
Minimum  2 weeks 
25% Percentile  6 weeks  
Median   14.5 weeks  
75% Percentile  39 weeks 
Maximum   80 weeks 
 
1any paresis in the affected limb, not related to nerve lesion,  2any sensory disturbances, not related to nerve lesion, 3time 
between onset of symptoms and obtaining of serum. 
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4.2.2 - CRPS immunoglobulins exhibit agonistic effects on the 
M2R and the β2AR in spontaneously beating cardiomyocytes 
The addition of affinity-purified IgG fractions of CRPS patients (60 mg/L) changed 
the beating frequency of spontaneously beating neonatal cardiomyocytes (Figure 
8), whereas healthy and disease control (PNP/NL) IgG fractions did not induce 
substantial change (deviation from basal beating rate: controls 1.02 ± 0.70, n = 10; 
CRPS 9.78 ± 10.57, n = 20; PNP/NL 0.88 ± 0.66, n = 9, ANOVA, p = 0.0041).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Functional effect of immunoglobulins (60 mg/L) of controls (n = 10), CRPS patients (n = 
20) or PNP/NL patients (n = 9) on spontaneously beating cardiomyocytes. CRPS antibodies 
induced changes (between -10.00 to 31.32 beats/min) in the beating frequency whereas controls 
and PNP/NL induced only very small changes (not higher than the ± 2.0 beats per min). ANOVA, p 
= 0.0041.  
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The neonatal cardiomyocyte model was established to measure and identify 
effects on different receptors, and a positive chronotropic action of CRPS IgG 
suggests an activation of  beta-adrenergic receptors (Wallukat and Wollenberger 
1987). Therefore, we tested the IgG effect with the nonselective beta-antagonist 
propranolol at 1 µM, which does not exhibit an intrinsic effect on the receptor at this 
dose (Wallukat and Wollenberger 1987).  
We confirmed indeed the lack of intrinsic activity of 1 µM  propranolol in cells 
treated with control IgGs (Figure 9). Instead a simply inhibition of the positive 
chronotropic effect of CRPS IgG by propranolol, we found a significant decrease in 
the beating rate below the control levels, suggesting that a second effect, 
previously masked, was present in the CRPS IgG fraction (controls 0.12 ± 0.43, n = 
10; CRPS -15.55 ± 1.28, n = 20; PNP/NL 0.36 ± 0.36, n = 9, Kruskal-Wallis test, p 
= 0.00001) (Figure 9). The addition of atropine (1 µM – which also has no intrinsic 
effect at this dose) led to a complete normalization of the beating rate (controls 0 ± 
0, n = 10; CRPS 0.2 ± 0.55, n = 20; PNP/NL 0 ± 0, n = 9; Kruskal-Wallis test, p = 
0.9975) (Figure 9), whereas the addition of 1 µM atropine to the IgG solutions 
without propranolol shifted the beating rate in 18/20 (90%) samples to a positive 
chronotropic effect, but had no influence on the control IgG fractions (Figure 10). 
Thus, it appeared that there were two independent effects in the IgG fraction of 
CRPS patients.  
To analyse the effect of each pathogenic activity, since they showed opposite 
properties, in further experiments we preincubated the cardiomyocytes with 
antagonists - propranolol or atropine - to block β2AR or M2R, respectively, before 
adding the IgG fractions.  
The positive chronotropic effect of IgG, in cells pre-treated with atropine, could be 
blocked by the beta2-specific antagonist ICI 118.551 (0.3 µM), but not with the 
beta1-specific bisoprolol (1 µM) (Figure 11A), strongly implying that the β2AR is 
one target antigen in CRPS. Blocking by atropine of the negative chronotropic 
effect of CRPS IgG, in cells pre-treated with propranolol, suggested that muscarinic 
acetylcholine receptors must be another antigenic target (Figure 11B). The main 
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muscarinic receptor expressed on cardiomyocytes is the M2 subtype (Hosey 
1992). Since endothelin receptors are also expressed on cardiomyocytes (Allen, 
Phuong et al. 2003), and their stimulation can induce marked decrease in 
cardiovascular function (Miller, Redfield et al. 1989), the endothelin receptor 
antagonist BQ-610 (1 µM) was used in propranolol-pretreated cells to validate that 
the negative chronotropic effect is not mediated by endothelin receptors (Figure 
11B).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Pharmacological modulation of immunoglobulins’ effect on spontaneously beating 
cardiomyocytes. The treatment with propranolol induced prominent decrease in the beating rate of 
cells treated with CRPS IgG in comparison with cells treated with control or PNP/NL IgG, showing 
that these antibodies have a beta-agonist effect along with an additional negative chronotropic 
effect (Kruskal-Wallis test, followed by Dunn’s Test, p = 0.00001; *different from CRPS groups in 
IgG treatment, p = 0.00001; # different from control and PNP/NL groups in propranolol treatment, p 
= 0.00001). Further treatment with atropine reversed the changes in beating rate to the level of 
controls (Kruskal-Wallis test, p = 0.9975) Values are expressed as mean of samples + S.E.M.  
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Figure 10. Dot blot representing the effect of each controls or CRPS IgG sample. Addition of 
propranolol or atropine to CRPS IgG shifted 90% of the samples to negative and positive range, 
respectively. Both drugs reversed the effect of 75% of all CRPS samples. For statistics see text. 
 
 
 
 
 
 
 
Co
ntr
ol 
IgG
CR
PS
 Ig
G
CR
PS
 Ig
G 
+ P
ro
p
CR
PS
 Ig
G 
+ A
tro
p
CR
PS
 Ig
G 
+ P
ro
p +
 A
tro
p-40
-30
-20
-10
0
10
20
30
40
Va
ria
tio
n 
in
 n
um
be
r o
f b
ea
ts
/m
in
RESULTS 
 
 55
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Effect of affinity-purified autoantibodies from CRPS patients in cultured cardiomyocytes 
and identification of putative target receptors. Cardiomyocytes were pretreated with atropine (A) or 
propranolol (B) as indicated in the panel. The chronotropic activity was blocked specifically by 0.3 
µM of ICI 118.551 (selective β2AR antagonist) and by 1 µM of atropine. The following treatment 
with antagonist of β1 (bisoprolol, 1 µM) and endothelin receptor-1 (BQ-610, 1 µM) showed that 
these receptors were not involved in the CRPS IgG activity. *different from IgG treatment (Kruskal-
Wallis test followed by Dunn's Test, p = 0.00001). Values are expressed as mean of samples + 
S.E.M. 
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4.2.3. The IgG effect of CRPS can be blocked by specific peptides 
derived from the second extracellular loop of the M2R and the 
β2AR  
Both G protein-coupled receptors (M2R and β2AR) consist of a common structural 
signature of seven membrane spanning domains, three intra- and three 
extracellular loops, an extracellular N-terminal, and an intracellular C-terminal tail. 
The second extracellular loop has been reported to be one of the main 
immunogenic regions of both receptors as well as one of the main targets for 
allosteric modulators (Elies, Fu et al. 1998; Peter, Eftekhari et al. 2003; May, Avlani 
et al. 2007; May, Leach et al. 2007). Therefore, 7 randomly selected CRPS IgGs 
were preincubated with short overlapping synthetic peptides corresponding to the 
second extracellular loop of the human β2AR and M2R, and then applied to the 
neonatal cardiomyocytes.  
Peptides with the sequences HWYRAT and ATHQEAI, but no other sequences 
derived from the second extracellular loop of the β2AR, blocked the positive 
chronotropic effect of CRPS IgG (Figure 12A). Moreover, synthetic peptides 
possessing the sequence of the first and third extracellular loop did not neutralize 
the IgG-mediated chronotropic effects (Figure 13). The peptides VRTVED and 
EDGECY were the only peptides from the second extracellular loop of the M2R 
which could block the negative chronotropic effect of CRPS IgG in propranolol-
pretreated cardiomyocytes (Figure 12B).   
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Figure 12. (A,B) Neutralization of CRPS IgG (n = 7) effect by peptides derived from extracellular 
sequences of the β2AR or the M2R on spontaneously beating cardiomyocyte. Cardiomyocytes were 
pre-treated with 1 µM propranolol (A) and 1 µM atropine (B). IgG fractions were pre-incubated with 
the peptides covering residues from the sequence of the extracellular loop of M2R (A) and β2AR 
(B). Two peptides from both receptors significantly blocked the chronotropic effect of 
immunoglobulins from CRPS patients. *different from SHAM and other peptides (ANOVA, Tukey’s 
test, p < 0.001). 
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Figure 13. Pre-incubation of CRPS IgGs with peptides derived from the first, second and third 
extracellular loop sequence of β2AR before addition to cardiomyocytes. Cells were pre-treated with 
atropine to block the agonistic of CRPS antibodies on M2R. Synthetic peptides possessing the 
sequence of the first and third extracellular loop did not neutralize the IgG-mediated chronotropic 
effects.  *different from SHAM (n = 7, Kruskal-Wallis test followed by Dunn's Test, p = 0.00001). 
Values are expressed as mean of samples ± S.D. 
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4.2.4. Peptide characterization by ELISA 
Affinity-purified IgG from CRPS patients and HC were tested by enzyme 
immunoassay using plates coated with peptides of the second extracellular loop of 
β2AR (HWYRAT and ATHQEAI) and M2R (VRTVED and EDGECY). Additionally, 
we tested the peptide sequences AINCYAN of the β2AR and CYIQFF of the M2R 
as negative controls, since these sequences were not recognized by CRPS IgGs 
(see Figure 12). We calculated a cut-off (in optical density units [OD]) on the basis 
of the mean ± 2.5x standard deviations of the values with negative control peptides 
for each receptor.  
We showed that 90% (18/20) of CRPS patients recognized at least one tested 
peptide. One peptide of each receptor was recognized by 55% of the CRPS, but 
none of the controls. 60% (12/20) of CRPS IgG fractions showed high affinity for 
β2AR sequences, 10/20 to both sequences, and one each only to HWYRAT or 
ATHQEAI. None of the samples showed binding to the control peptide AINCYAN 
(Figure 14A, Appendix 1). 90% of the CRPS IgG showed binding to one or two of 
the M2R-derived peptides. 13/20 CRPS IgG samples recognized the sequence 
VRTVED, 17/20 the sequence EDGECY, while none of them recognized the 
CYIQFF control peptide (Figure 14B, Appendix 1). With exception of one control 
binding to VRTVED, IgG of healthy controls did not show specific binding to any of 
the peptides tested (Figure 14).  
We noticed a positive correlation between samples that recognized both peptides 
of β2AR (Pearson r = 0.6037; p = 0.0048; n = 20) and these with VRTVED of M2R 
(Pearson r = 0.7040; p = 0.0005; n = 20 with HWYRAT and Pearson r = 0.5530; p 
= 0.0114; n = 20 with ATHQEAI). EDGECY was recognized by the majority of 
CRPS patients (85% or 17/20, see Figure 14B) and therefore did not show any 
significant correlation with other peptides (VRTVED: Pearson r = 0.1040; p = 
0.6626; n = 20. HWYRAT: Pearson r = 0.1229; p = 0.6058; n = 20. ATHQEAI: 
Pearson r = 0.2886; p = 0.2172; n = 20) . Indeed, only three samples of CRPS 
patients did not showed raised levels of IgG antibodies to the sequence EDGECY 
of M2R, one of them presented however raised levels to both sequences 
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HWYRAT and ATHQEAI of the β2AR, and other two did not recognized any of the 
tested sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. CRPS antibodies detected by ELISA. (A) Antibodies against β2AR peptides HWYRAT 
and ATHQEAI were found in 12/20 CRPS patients - 10/20 (50%) samples recognized both 
sequences. No CRPS IgG recognized the peptide AINCYAN. None of control samples showed 
affinity to any β2AR peptide. (B) 13/20 (65%) CRPS IgG samples showed affinity the sequence 
VRTVED and 17/20 (85%) the sequence EDGECY of the M2R, while none of them recognized the 
sequence CYIQFF. One control sample recognized VRTVED sequence. Cut-off (in optical density 
units [OD]), marked as horizontal line, on the basis of the mean + 2.5x standard deviations of the 
values with negative control peptides for each receptor. 
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4.2.5. Receptor autoantibodies in CRPS do not cross-react 
between M2R and β2AR  
Since two functionally active autoantibodies could be detected in the majority of 
CRPS patients, we addressed a possible cross-reactivity between them using a 
pharmacological manipulation with receptor antagonists and peptides. We 
preincubated 6 randomly selected IgG of CRPS patients with sequences of β2AR 
or M2R peptides and, in parallel, incubated cardiomyocytes with either propranolol 
or atropine. The intention was to determine if those antibodies responsible for the 
activation of M2R can be blocked by peptides of the β2AR or vice versa. In the first 
experiment, we tested the ability of M2R antibodies to bind peptides of the β2AR. 
CRPS IgG fractions were preincubated with the two β2AR peptides HWYRAT and 
ATHQEAI, both of which were able to block the β2-agonistic effect of the CRPS 
IgG fractions. Another peptide without blocking effect, AINCYAN, was used as a 
negative control. Cardiomyocytes were treated with propranolol or atropine and 
then incubated with the pre-blocked CRPS IgG. In the propranolol-treated cells, the 
preincubated IgG induced a negative chronotropic effect, indicating (1) that the β2-
agonistic effect can be removed by preincubation with the two peptides from the 
second extracellular loop of the β2AR and (2) that anti-M2R antibodies were still 
present and did not bind to the β2AR peptides (Figure 15A). Vice versa, CRPS IgG 
pre-blocked with the M2R peptides VRTVED and EDGECY was still able to induce 
a positive chronotropic effect in atropine pre-treated cardiomyocytes (Figure 15B). 
Both experiments indicate that no cross-reactivity occurs between the anti- β2AR 
and the anti-M2R antibodies. 
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Figure 15. Evaluation of possible cross-reactivity between CRPS IgGs. No cross reactivity could be 
observed between M2R and β2AR antibodies. In panel (A) antibodies were preincubated with 
correspondent β2AR peptides while cardiomyocytes were pre-treated with propranolol (1 µM) or 
atropine (1 µM) as displayed. M2R autoantibodies were not blocked by peptides corresponding to 
residues of β2AR and showed negative chronotropic activity in propranolol-treated cells. However, 
β2AR antibodies were successfully blocked by HWYRAT and ATHQEAI peptides and showed no 
effect in atropine-pretreated cells. (B) Vice versa, CRPS IgG pre-blocked with VRTVED and 
EDGECY was still able to induce a positive chronotropic effect in atropine pre-treated 
cardiomyocytes - β2AR agonistic effect was not impaired by M2R peptides. *different from (A) IgG + 
AINCYAN and (B) IgG + CYIQFF (n = 6, Kruskal-Wallis test followed by Dunn's Test, p < 0.001). 
#different from the other cardiomyocyte treatment (propranolol or atropine) for the same IgG + 
peptide (n = 6, Kruskal-Wallis test followed by Dunn's Test, p < 0.001). Values are expressed as 
mean of samples + S.E.M. 
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4.3. Experiment set 3: Immunoglobulins subclasses of pathogenic 
antibodies 
4.3.1. IgG subclasses characterization of CRPS antibodies 
The autoantibodies against the β2AR and the M2R belong to the IgG class. IgG 
includes the subclasses IgG1-4. These subclasses differ in their immunological 
function, and the subtype identification of pathogenic antibodies might indicate 
which T helper (Th) cell subset is mostly involved in an autoimmune response, and 
whether the autoantibodies may be able to bind complement. Using anti-IgG1-4 to 
preincubate and precipitate the patients IgG subclasses. We demonstrate that 
pathogenic β2AR antibodies belong to IgG1 and IgG2 subtypes (Figure 16A), 
whereas the M2R antibodies are IgG1 and IgG3 subtypes (Figure 16B). 
4.4. Experiment set 4: CRPS pathogenic antibodies bind to the 
surface of hM2R- and hβ2AR-transfected CHO cells 
To confirm whether CRPS autoantibodies bind specifically to the β2AR and M2R, 
we incubated CHO cell line wild type or CHO cells expressing hβ1AR, hβ2AR, or 
hM2R with HC, CRPS, or PNP/NL IgGs, and assessed the surface binding against 
the non-permeabilized cells using flow cytometry, an established method to detect 
surface binding of human autoantibodies. 55% (11/20) of the CRPS patients, none 
of the controls, and only one patient of the PNP/NL group showed binding to either 
hβ2AR CHO cells (ANOVA, p = 0.0077) or hM2R CHO cells (ANOVA, p = 0.0202) 
or both (hβ2AR, n = 3; hM2R, n = 3; both receptors, n = 5) (Figure 17A,B). CHO 
cells transfected with hβ1AR were used as a control, two patients in the PNP/NL 
group, and one of the CRPS but none of the healthy controls showed binding to 
these cells (ANOVA, p = 0.2060) (Figure 17C). There was no binding to wild type 
CHO cells in any group (ANOVA, p = 0.2854) (Figure 17D).  
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Figure 16. Identification of IgG subclass of CRPS autoantibodies. Pathogenic antibodies of CRPS 
patients (n = 5) were preincubated with mouse anti-human IgG1, -2, -3 and -4 antibodies before the 
incubation with spontaneously beating cardiomyocytes and then changes in the beating rate were 
assessed. (A) β2AR antibodies are mainly IgG1 and IgG2 (Kruskal-Wallis test, p = 0.0014). (B) 
M2R antibodies are predominantly IgG1 and IgG3 (Kruskal-Wallis test, p = 0.0012). *mean different 
from whole IgG effect (Kruskal-Wallis test, Dunn's Test, p < 0.01). Values are expressed as mean of 
samples + S.E.M. 
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Figure 17. Binding of controls (n = 10), CRPS (n = 20), or PNP/NL (n = 9) IgG samples to CHO cell 
line expressing (A) hβ2AR, (B) hM2R, (C) hβ1AR, or (D) wild type. No significant difference could 
be observed in binding to CHO wild type cell (ANOVA, p = 0.2854) or hβ1AR (ANOVA, p = 0.2060) 
between controls, CRPS or PNP/NL IgGs. CRPS patients have however more and higher binding to 
CHO cells expressing hβ2AR (ANOVA, Tukey’s test, p = 0.0078) or hM2R (ANOVA, Tukey’s test, p 
= 0.0202) than controls, neuropathy patients or peripheral nerve lesions patients (PNP/NL). Cut-off, 
marked as horizontal line, was determined as mean of the controls + 2.5x standard deviations for 
each cell line. 
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Since the percentage of positive binding was similar to our previous results with 
differentiated autonomic cells (40% surface binding). We additionally detected 
upregulation of these receptors in BMP-2/RA differentiated SH-SY5Y 
neuroblastoma cells (Figure 18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Expression of β2AR and M2R in SH-SY5Y cells non-differentiated and differentiated 
with RA and/or BMP-2. After differentiation total RNA was prepared and subjected to cDNA 
synthesis. This cDNA was used for PCR amplification of β2AR, M2R and PBGD. SY5Y cells 
differentiated with the combination of BMP-2/RA showed increased expression of β2AR and M2R. 
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4.5. Experiment set 5: Functional assays 
4.5.1. Pathogenic antibodies show agonistic-functional effects but 
do not induce desensitization 
Affinity purified antibodies from CRPS patients were added to the medium of 
cultured cardiomyocytes pre-treated either with atropine (Figure 19A) or 
propranolol (Figure 20A), and their effect was investigated as a function of time.  
In cells pre-treated with atropine, IgG showed a positive chronotropic action. This 
effect was stable along the time and maintained for about 6 h (Figure 19A), in 
contrast with the sharp effect of clenbuterol that waned along the time (Figure 
19B). CRPS IgG positive chronotropic property was completely reversed by the 
β2AR antagonist ICI 118.551 (0.3 µM). Further, after a washout procedure and 
addition of fresh medium, the stimulation of autoantibody-stimulated 
cardiomyocytes with agonist clenbuterol (Figure 19A) promoted in both patients an 
increase in beating frequencies similar to that induced by the agonist alone in the 
first stimulation, as displayed in the Figure 19B (response in about 45 beats/min). 
Thus, the desensitization phenomenon normally induced by the agonist did not 
occur when cells were pre-exposed to autoantibodies. The desensitization 
phenomenon could on the other hand be demonstrated in cardiomyocytes re-
stimulated with clenbuterol, since the second stimulation with agonist induced only 
a mild response - four times lower than that induced by the first stimulation (see 
Figure 19B). 
The same behaviour was observed for the M2R agonistic effect of affinity-purified 
CRPS IgGs in cardiomyocytes pre-treated with propranolol. In this case, CRPS IgG 
decreased the beating frequencies in a specific manner (Figure 20A) but not like 
the agonist carbachol (Figure 20B), and no longer induced desensitization - clearly 
observed after re-exposition to agonist carbachol (Figure 20B). 
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Figure 19. Time dependency of the chronotropic effect induced by pathogenic antibodies directed 
against the second extracellular loop of the β2AR. Cells were pre-treated with atropine to block the 
M2R agonistic effect of IgGs. (A) The positive chronotropic effect of autoantibodies was sustained 
until the addition of selective β2AR antagonist (ICI 118,551). Addition of agonist clenbuterol 
increased the beating rate in the same order of magnitude as that induced by the agonist alone 
(about 45 beats/min - see stimulation with clenbuterol in panel B), showing that no desensitization 
occurred after exposition to antibodies. (B) Typical receptor desensitization induced by the re-
exposition to agonist clenbuterol. The agonistic effect wane along the time and was completely 
abolished after washing out with fresh medium. A second exposition to agonist did not induce the 
same changes in beating rate induced by the first administration. Values are expressed as mean of 
replication in different cultures + S.E.M. *different from 180 min time point (n = 8, Friedman test, 
Dunn's Test, p < 0.01). **different from 5 min time point. #different from 5 min time point (n = 8, 
Friedman test, Dunn's Test, p < 0.01). 
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Figure 20. Time dependency of the chronotropic effect induced by M2R antibodies. 
Cardiomyocytes were pre-treated with propranolol. The effect of autoantibodies was sustained 
along the time. After 3 washes and a replace of new medium, agonist carbachol (10 µM) displayed 
a negative chronotropic effect similar to the first administration observed in the panel B (about -25 
beats/min), showing that no desensitization occurred after treatment with antibodies. (B) Typical 
receptor desensitization induced by the re-exposition to agonist carbachol. The agonist effect wane 
along the time and was completely abolished after washing out with fresh medium. The second 
exposition to agonist did not induce the same decrease in beating rate induced by the first 
administration. Values are expressed as mean of replication in different cultures + S.E.M. *different 
from 180 min time point (n = 8, Friedman test, Dunn's Test, p < 0.01). **different from 5 min time 
point (n = 8, Friedman test, Dunn's Test, p < 0.01). #different from 5 min time point (n = 8, Friedman 
test, Dunn's Test, p < 0.01). 
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4.5.2. β2AR and M2R autoantibodies do not downregulate their 
corresponding receptors on the cell surface 
In myasthenia gravis, binding of autoantibodies to the nicotinic acetylcholine 
receptor leads to a downregulation of nAChR at the neuromuscular junction (Lang 
and Vincent 2003). We therefore incubated β2AR- and M2R-transfected CHO cells 
with patient and HC IgG. After 24h (Figure 21A) and 48h (Figure 21B), there was 
no downregulation of the β2AR or M2R on the cell surface as detected by flow 
cytometry. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Receptor expression of β2AR- or M2R-transfected CHO cells after incubation with 
CRPS IgG or control IgG for 24 (A) or 48 (B) hours. Flow cytometric surface expression analysis of 
β2AR or M2R on the transfected CHO cells revealed no difference in the receptor expression after 
incubation with CRPS IgG compared to control IgG after 24 (A) or 48 (B) hours. Data are 
represented as mean of triplicates ± S.D. Mann Whitney test (n = 9; β2AR 24 h p = 0.863, M2R 24 h 
p = 0.90, β2AR 48 h p = 0.37, M2R 48 h p = 0.28) MFI: mean fluorescence intensity.  
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4.5.3. β2AR and M2R autoantibodies cause receptor dependent 
increase in cytosolic Ca2+ concentration in transfected cell lines. 
Activation of both β2AR (Magne, Couchie et al. 2001) and M2R (Sorimachi, 
Furukawa et al. 1995) by agonists increase intracellular Ca2+ concentration. 
Muscarinic receptor-agonist bethanechol (100 µM) as well as the β2-agonist 
clenbuterol (30 µM) induced a prominent increase in intracellular Ca2+ 
concentration in hM2R or hβ2AR transfected cells, respectively (Figure 22A). 
Further, we tested the effect of 6 randomly selected CRPS patients and 3 controls 
IgG in wild type or transfected CHO cells. HC did not induced any substantial 
changes in intracellular Ca2+ concentration (Figure 22B). CRPS IgG but none of HC 
IgG evoked a significant increase of the fura-2 ratio signal by 0.087 ± 0.056 on 
average (n = 6, paired Student’s t-test, p = 0.0128) in CHO cells expressing 
hβ2AR. The IgG effect on the β2AR could be blocked by propranolol (1 µM) in 5/6 
samples (Figure 23A, other patients in Appendix 2 and 3).  
Only 2/6 CRPS patients and none of HC induced an increase of the fura-2 signal in 
hM2R CHO cells (n = 6, paired Student’s t-test, p = 0.1929). The effect of these 
two sera was successfully blocked when cells were previously treated with atropine 
(1 µM) (Figure 23B, other patients in Appendix 4). No influence of the IgG fractions 
could be observed in wild type CHO cells (Figure 24).  
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Figure 22. (A) Changes in the intracellular Ca2+ concentration induced by agonists. Beta2-agonist 
clenbuterol (30 µM) and muscarinic receptor-agonist bethanechol (100 µM) induced a prominent 
Ca2+ influx in hM2R- or hβ2AR-CHO cells, respectively. (B) Illustration of one samples of HC in WT, 
hβ2AR-, M2R-CHO cells. HC IgG did not induce any substantial changes in intracellular Ca2+ 
concentration. 
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Figure 23. Changes in the intracellular Ca2+ concentration induced by putative autoantibodies of 
CRPS patients. (A) Illustration of one samples showing that CRPS IgG (60 mg/L) induced an 
increase in the fura-2 ratio in CHO cell line overexpressing hβ2AR. The pre-treatment with 1 µM 
propranolol inhibited the effect of IgG (60 mg/L) in 5/6 cases. (B) Illustration of the effect of one 
sample in cells overexpressing hM2R. 2/6 CRPS IgG (60 mg/L) and the agonist bethanechol (100 
µM) induced an increase in the fura-2 ratio, blocked by preceding treatment with the antagonist 
atropine (1 µM). For statistics see text. 
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Figure 24. Effect of affinity-purified CRPS IgG in WT-CHO cells. CRPS autoantibodies did not 
induce any substantial change in the intracellular Ca2+ concentration in wild type CHO cells. Paired 
Student’s t-test, p = 0.0607. 
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4.5.4. Association with clinical data 
We did not identify any significant correlation (Spearman’s correlation, p > 0.05) 
between the presence of functional active autoantibodies to one and/or two 
receptors, surface-binding to receptor-transfected CHO cell line or Elisa optical 
density values for different peptides and clinical / epidemiological data (gender, 
age, CRPS I or II, warm or cold, CRPS duration, inciting event, pain score, affected 
limb, sensory or motor impairment, vasomotor, sudomotor or trophic changes) of 
the analyzed CRPS patients. 
4.6. Experiment set 6: CRPS antibodies do not induce cytotoxicity 
The rational was to measure the cytotoxic effect of different patients’ IgG on 
receptor-transfected CHO cell lines. Cells were first plated at different densities for 
24 h in 1% FCS medium to find out the right cell density for further experiments. It 
has been deduced that 10,000 cells per well is the optimum cell density which has 
a linear function in the cytotoxicity assay. Ten thousands cells per well were then 
incubated with purified IgGs (120 mg/L) in 96 well plates for 24 h and later the 
cytotoxicity was measured using LDH cytotoxicity assay kit. There could not be 
shown any cytotoxic effects of CRPS IgG (ANOVA one-way, p > 0.05). None of the 
healthy controls showed any cytotoxicity. The results obtained after 24 h incubation 
with IgGs are summarized in percentage of cytotoxicity in the Figure 25.  
Additionally, we tested CRPS, PNP/NL or HC affinity-purified IgGs in hβ2- and 
hM2-CHO cell lines for their ability to influence cell growth and viability or to induce 
cytotoxicity using cell proliferation/cell viability WST-1 assay. Cells were incubated 
with IgGs for 24 h, WST-1 reagent was added and then WST-1 cleavage was 
detected by ELISA plate reader after 1 h, 2 h and 3 h. Neither CRPS nor PNP/NL 
IgGs influenced cell growth or viability of any transfected CHO cells in comparison 
with HC samples (ANOVA one-way, p > 0.05). Moreover, no cytotoxic effect could 
be demonstrated after 24 h treatment with IgG in none of the samples tested. 
Positive control of cytotoxicity was the treatment with 2% Triton-100 (Figure 26). 
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Figure 25. Purified IgGs from CRPS patients tested with hβ2AR- and hM2R-CHO cell lines for their 
cytotoxic effects using LDH assay. Cells were incubated with IgGs for 24 h and then supernatant 
was used to detect cytotoxicity using LDH cytotoxicity assay. No cytotoxicity was observed in 
receptor transfected cells (ANOVA one-way; hβ2-CHO, p = 0.3491; hM2-CHO, p = 0.8851). 
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         A) 
 
 
 
 
 
 
 
 
 
 
         B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Purified IgGs tested in hβ2- and hM2-CHO cell lines for their cytotoxic effects using cell 
proliferation or cell viability WST-1 assay. Purified IgGs did not influence cell viability as well as did 
not shown any cytotoxic effect in hβ2-CHO (A) and hM2-CHO (B) cell lines. Positive control of 
cytotoxicity was the treatment with 2% Triton-100. One-way ANOVA, hβ2-CHO 1 h p = 0,5823; 2h, 
p = 0,4610; 3h, p = 0,7248; hM2-CHO 1 h, p = 0,2102; 2 h, p = 0,9927; 3 h, p = 0,7735. 
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V - DISCUSSION 
A significant number of CRPS patients have autoantibodies against a surface 
epitope of autonomic neurons. Our results further indicate that this surface antigen 
is weakly expressed in undifferentiated neuroblastoma cells, but can be induced by 
differentiation into a distinct phenotype, preferentially cholinergic. Further, we have 
defined two specific target antigens for these autoantibodies - M2R and β2AR - 
supporting an autoimmune hypothesis in CRPS. The antibodies bind to specific 
epitopes of the second extracellular loop of the two receptors, and do not cross-
react. Both antibodies exhibited functional effects on neonatal cardiomyocytes in 
vitro, implying that they could interfere with the function of these receptors, in the 
peripheral and possibly also in the central nervous system in vivo. Moreover, 
antibodies were neither able to induce receptor desensitization and/or 
downregulation of the target receptor nor cell cytotoxicity. All in all these results 
provide further evidence that autoimmunity against the autonomic nervous system 
may be involved in the pathogenesis of CRPS. 
The complex regional pain syndrome (CRPS) may develop after peripheral limb 
trauma. Clinical symptoms of acute CRPS are characterized by signs of 
inflammation (pain, edema, red skin) and neurologically mediated disturbances 
(loss of vasomotor control, increased or decreased sweating, urogenital symptoms) 
that result from a contribution of the sympathetic and/or peptidergic innervation of 
the target tissue (Chancellor, Shenot et al. 1996; Wasner, Schattschneider et al. 
2001; Albrecht, Hines et al. 2006), and later on in the course of chronic CRPS, 
abnormal central nervous system plasticity. Pain and hyperalgesia might be related 
to sensitization of primary and secondary nociceptive neurons by e.g. 
proinflammatory cytokines (Maihofner, Handwerker et al. 2005; Sabsovich, Guo et 
al. 2008), with increased release of neuropeptides (CGRP, SP) from these 
sensitized peripheral nociceptors (Weber, Birklein et al. 2001; Guo, Offley et al. 
2004). The origin of the variable sympathetic disturbances is largely unknown, and 
both peripheral (Uceyler, Eberle et al. 2007) and central disturbances (Moseley, 
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Zalucki et al. 2008) have been discussed. The reason why only some patients 
develop CRPS after trauma, while the majority does not, remains elusive. 
We postulated the immune system is involved in the development of CRPS, since 
antibodies have been demonstrated to recognize autonomic nervous system 
structures in some patients (Blaes, Schmitz et al. 2004). In the present study, we 
sought to identify the target autoantigen and characterize putative functional 
properties of these autoantibodies. We confirmed the presence of putative 
antibodies, and showed that these antibodies display agonistic properties on M2R 
and β2AR in most CRPS patients tested (90%). It is not clear whether these 
antibodies are already present before the injury happens or are produced after 
injury and the following inflammation. Indeed, the exposition of autoantigens from 
autonomic neurons to the immune system might induce the production of 
autoantibodies. Autoimmunity is though mediated by a variety of complex 
mechanisms, molecular and cellular events, and responses. It is worthy pointing 
out that even if a given autoimmune disease was to be initiated primarily by a 
single trigger, other events and regulating mechanisms come into play, thereby 
adding complexity to the process.  
Predisposition to a given autoimmune response requires the requisite allele(s) that 
controls antigen presentation by antigen-presenting cells for T cell recognition. 
Indeed, CRPS has been associated to some HLA alleles - DQ1, DR13, DR15 and 
the centromeric regions of the HLA class 1 antigens were linked to CRPS (Mailis 
and Wade 1994; Kemler, van de Vusse et al. 1999; van Hilten, van de Beek et al. 
2000; van de Beek, Roep et al. 2003; Meier, Alexander et al. 2006). Although 
association with HLA alleles does not necessarily implicate an immune etiology of 
a disease, yet many autoimmune diseases have distinct HLA associations. The 
presence or absence of appropriate MHC determines whether the potential 
autoantigen will be presented for immune recognition and responses or not. 
Furthermore, proteins to which the immune system is ordinarily self-tolerant might, 
if altered, elicit autoimmune responses (Yu, Mamchak et al. 2003). Sequestered 
proteins normally sheltered from immune recognition once exposed to the immune 
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system become immunogenic and targets of immune effector functions. Tissue 
damage, inflammation and its mediators that precede the development of CRPS 
could play a pivotal role in exposing or modifying self-proteins in inflammatory sites 
to the immune system. 
Other alterations can occur because of disruption in the levels or activity of 
regulatory proteins, and as a consequence disturbed activity of regulatory cells. 
Mutation in certain alleles can cause immune dysregulation and lead to systemic 
autoimmunity such as TNF-α. CRPS patients display significant increases in 
proinflammatory cytokines (TNF-α, interleukin-1β, -2, and -6) in local blister fluid, 
circulating plasma and cerebrospinal fluid, and higher plasma levels of soluble 
TNF-α. Interestingly, administration of a TNF-α antibody (infliximab) produced 
notable reductions in CRPS symptoms in some patients (Huygen, Niehof et al. 
2004). Further arguments for an involvement of immune system dysregulation in 
CRPS are studies showing altered monocyte reactivity to interferon-γ stimulation 
(Hartrick 2002). 
Many autoimmune responses have been shown to emerge following infection by a 
pathogen, whose protein(s) possess structural similarities in some of its epitopes to 
host proteins. Thus, antibodies developed against a pathogen might cross-react 
with a self-protein and act as autoantibodies. The involved autoantigen becomes 
then a source for persistent stimulation (Blank, Barzilai et al. 2007). There are 
reports about the increased prevalence of parvovirus B19 IgG in CRPS patients 
(van de Vusse, Goossens et al. 2001; Gross, Tschernatsch et al. 2007). Parvovirus 
B19 infection induces autoantibody production and might lead to autoimmune 
diseases (Holm, Hansen et al. 1995). A comparable molecular mimicry causing 
autoimmune inflammation of the nervous system has been described in 
campylobacter-associated polyradiculitis. Interestingly, an association of 
campylobacter-positive serology to CRPS has also been described (Goebel, Vogel 
et al. 2005; Willison 2005). Accordingly, one may assume that immunoglobulins 
can arise independently during an infection but only later on function as templates 
for the generation of pathogenic autoantibodies.  
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Imbalance in factors involved in immune responses to an infectious pathogen, such 
as cytokines and associated mediators or receptors, can contribute to enhance 
antigen mimicry in infections (Tsang and Valdivieso-Garcia 2003). Peripheral 
trauma, in particular if it is accompanied by partial peripheral nerve lesion, causes 
a rapid release of cytokines and neurotrophins (Sabsovich, Guo et al. 2008; 
Sabsovich, Wei et al. 2008), which activate and sensitize primary and probably 
also spinal afferents (Maihofner, Handwerker et al. 2005). Activation and 
sensitization of primary afferents also cause an increase of neuropeptide release 
into the affected body region (mainly substance P and CGRP). Chronic release of 
neuropeptides might not only be responsible for the clinically evident inflammatory 
CRPS symptoms but also contribute for immune dysregulation (Weber, Birklein et 
al. 2001). 
The sum of these entire factors can contribute to the breakdown of self-tolerance. 
Autoantibodies may emerge through a process of clonal selection if self-tolerance 
is disturbed, as a result of inflammatory processes and tissue damage. As a 
consequence, it might lead to the production or spreading of detected 
autoantibodies. What follows is the exposition of autoantigens and/or dysregulation 
of the immune system, resulting in the emergence of an autoimmune disease. 
Indeed, no single hypothesis until now could explain all features of CRPS. Whether 
such syndrome could be the result of the development of autoantibodies needs still 
to be further investigated. However, the identification of agonistic-like 
autoantibodies against M2R and β2AR receptors must not be underestimated, 
since they showed important agonistic properties and do not induce receptor 
desensitization or downregulation of target receptors. One may speculate that the 
persistent stimulation of these receptors by functionally active autoantibodies could 
well lead to autonomic dysregulation observed in CRPS. 
Impairment of sympathetic function has been repeatedly shown in CRPS including 
disturbances of vasomotor (Birklein, Riedl et al. 1998; Wasner, Schattschneider et 
al. 2001) and sudomotor function (Birklein, Kunzel et al. 2001). The origin of these 
sympathetic nervous system symptoms in posttraumatic CRPS is still widely 
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unclear. Human and animal studies strongly support the concept of an adrenergic 
supersensitivity in CRPS (Drummond, Skipworth et al. 1996; Chemali, Gorodeski 
et al. 2001; Gibbs, Drummond et al. 2008; Drummond 2009). Vasoconstriction in 
the affected extremity could be triggered by injection of lower doses of 
noradrenaline than in the unaffected side. Correspondingly, Jorum et al. showed 
that sensitized mechano-insensitive nociceptors are activated by endogenous 
sympathetic activity and thereby may contribute to sympathetically maintained pain 
observed in a subset of CRPS patients (Jorum, Orstavik et al. 2007). The 
adrenergic sensitivity that appears to develop in primary sensory afferents after 
nerve injury and inflammation is consistent with the notion that dysfunction of the 
sympathetic activity might be due to the effect of functionally active autoantibodies 
binding to β2AR receptors of peripheral autonomic neurons, target cells or immune 
cells in CRPS.  
Though antibodies showed an agonistic effect on M2R and β2AR, the epitope 
sequences identified correspond to common allosteric binding sites for allosteric 
modulators. These have frequently the property of enhancing binding and effect of 
the agonists mostly stabilizing the receptor in its “active” conformation (Lebesgue, 
Wallukat et al. 1998; Peter, Eftekhari et al. 2003; May, Avlani et al. 2007; 
Hernandez, Nascimento et al. 2008). If antibodies activate receptors, in one way or 
another, the endogenous sympathetic discharge might trigger activity in primary 
sensory fibers. The fact that noradrenaline injection in the skin induces pain in 
CRPS patients as well as rekindle pain that had subsided after sympathectomy 
endorsed this hypothesis. Moreover, axon-reflex sweating induced by 
iontophoresis of phenylephrine was greater in the affected side than in the 
unaffected side, and was greater than in control subjects or resolved CRPS 
(Chemali, Gorodeski et al. 2001). Though phenylephrine is a well known alpha 1 
adrenergic receptor agonist, it has the property of stimulating also βAR (Torp, 
Tschakovsky et al. 2001). 
Wasner et al. suggested that sympathetic vasoconstrictor reflexes and venous 
levels of norepinephrine and its metabolites are diminished as a result of 
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decreased release of transmitter from postganglionic sympathetic fibers on the 
affected side (Wasner, Schattschneider et al. 2001). This is consistent with the 
notion that persistent agonistic stimulation of β2AR by immunoglobulins and the 
following supersensitivity might lead to reduction of neurotransmitter release in the 
affected limb. Conversely, it seems reasonable to assume that the effect of 
circulating antibodies would not be restricted to the affected limb. Indeed, there is 
evidence for a subclinical contralateral sympathetic dysfunction in CRPS, specially 
in the early stage (Rosen, Ostergren et al. 1988; Bej and Schwartzman 1991; 
Kurvers, Jacobs et al. 1996). 
Additionally, autoantibodies against M2R might contribute to autonomic symptoms 
in CRPS. Cholinergic receptor antibodies may explain associated features of 
autonomic dysfunction in Sjögren’s syndrome (Waterman, Gordon et al. 2000). 
Cholinergic neurons are all central autonomic neurons and the peripheral 
parasympathetic and sudomotor neurons (Low 1997). Thus, autonomic 
disturbances induced by anticholinergic autoantibodies might be very different in 
CRPS patients and include vasomotor (Wasner, Schattschneider et al. 2001), 
sudomotor (Birklein, Sittl et al. 1997), cardiovascular (Meier, Alexander et al. 2006) 
and urogenital (Chancellor, Shenot et al. 1996) symptoms.  
Functional autoantibodies that act at ion channels or receptors disrupting 
autonomic or cardiovascular functions have been described in many autoimmune 
diseases, and are often pathogenic (Waterman, Lang et al. 1997; Waterman, 
Gordon et al. 2000; Goldblatt, Gordon et al. 2002; Gleicher, Barad et al. 2007; 
Jackson, Gordon et al. 2008; Maciejewska-Rodrigues, Al-Shamisi et al. 2010). In 
well characterized autoantibody-mediated neuroimmunological diseases, such as 
myasthenia gravis or Lambert-Eaton myasthenia syndrome, pathogenically 
relevant autoantibodies are directed against voltage- or ligand-gated ion channels 
and their associated proteins at the neuromuscular junction (Lang and Vincent 
2003). Surface antibodies not only play a pivotal role in the pathophysiology of 
neuroimmunological diseases but also in cardiologic diseases like autoimmune- or 
Chagas-associated cardiomyopathy (Wallukat and Wollenberger 1987; Goin, 
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Borda et al. 1994; Lang and Vincent 2003). 
Functional active autoantibodies against G-protein coupled receptors with 
pathophysiologic relevance have been clinically and experimentally demonstrated 
in patients with heart diseases such as Chagas’ disease (β1-, β2AR and M2R 
antibodies), dilated cardiomyopathy (β1AR and M2R antibodies), pre-eclampsia 
(angiotensin 1 receptor antibodies) and essential hypertension (alpha 1 adrenergic 
receptor antibodies) (Wallukat, Fu et al. 1999; Fu, Herlitz et al. 2000; Wallukat, 
Nissen et al. 2000; Zhou, Zhang et al. 2008). We here identified autoantibodies 
against two autonomic receptors in patients with CRPS - the M2R and the β2AR, 
which are characterized by functional effects in vitro. Similar pattern of 
autoantibodies against the M2R and β2AR has been reported in Chagas’ disease. 
However, the antibodies found in CRPS have different epitope specificity and also 
different functional properties. In contrast to the M2R antibodies in Chagas’ 
disease, agonistic M2R antibodies in CRPS bind only to the second extracellular 
domain of the receptor; this is similar to the M2R autoantibodies in patients with 
dilated cardiomyopathy. 
Autoantibodies against M2R occur in patients with dilated cardiomyopathy in 
combination with beta-adrenergic receptor antibodies (Stavrakis, Kem et al. 2010). 
Most groups failed to demonstrate the importance of β2AR reactive autoantibodies 
in dilated cardiomyopathy. Furthermore, beta2 blockage in dilated cardiomyopathy 
increased the contractility in cardiomyocytes suggesting an antagonistic effect of 
these antibodies. In contrast, the positive chronotropic effect of the CRPS IgG 
demonstrated an agonistic effect. Blocking the CRPS anti-β2AR antibodies with 
specific peptides revealed an additional functional epitope (ATHQEAI).  
The question whether autoantibodies are simply epiphenomenon or directly linked 
to pathogenesis of CRPS remains unclear. In fact, 90% of CRPS IgG were 
detected by ELISA to bind to at least one of reported peptides from the second 
extracellular domain of these receptors; and, the same percentage showed 
functional effect on cardiomyocytes assay. Though the immunogenicity of proteins 
is mostly inherent to their three dimensional conformation, an ELISA displaying 
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small-peptides in linear sequences was very efficient in detecting CRPS 
antibodies. Cardiomyocyte bioassay has also been proved to be a very sensitive 
method for detection of receptor antibodies (Wallukat, Fu et al. 1999), and 
therefore showed high detection efficiency. It is very important to mention that we 
performed these experiment many times and the effect was entirely replicable for 
all patients enabling us to affirm these methods as sensitive in detecting CRPS 
antibodies. 
One explanation why antibodies could not be demonstrated in all patients might 
well be the inclusion of patients according to the IASP research criteria. Although 
all these patients meet the IASP criteria for CRPS, it is unclear whether they all 
have the same physiopathology. Even by clinical criteria, there seem to be 
subtypes within these groups. For instance, patients with “warm” and “cold” CRPS 
do not only differ in the temperature of the affected limb, but also show a distinct 
clinical pattern including differences in sensory impairment measured by 
quantitative sensory testing or differences in the frequency of associated dystonia 
(Eberle, Doganci et al. 2009). Therefore, patients with autoantibodies might 
represent a special pathophysiological subgroup of CRPS. It is noteworthy that 
pathogenic hβ1AR autoantibodies - classically proven to play a crucial role in the 
pathophysiology of dilated cardiomyopathy by reducing cardiac function and 
inducing chronic heart failure - are also not detected in all dilated cardiomyopathy 
patients, but rather in less than 50% (Jahns, Boivin et al. 1999).  
Approximately 40-50% of CRPS patients were demonstrated to have surface-
binding antibodies detected by flow cytometry with differentiated autonomic 
neurons or CHO cells overexpressing hβ2AR or hM2R. One reason for the lower 
detection in this case might be the method used. If antibodies are low-affinity 
binding IgGs, our method (flow cytometry) is not able to discriminate the specific 
binding from background. Low-affinity binding autoantibodies have also been 
recently found in patients with myasthenia gravis where no anti-nAChR antibodies 
could be found in normal tests (Leite et al. 2008).  
Neuroblastoma cells are a well-established model for the differentiation of 
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dedifferentiated cells into a variety of neuronal subtypes (Gomez-Santos, Ferrer et 
al. 2002). The high binding to differentiated autonomic neurons in comparison to 
neuroblastoma cells was surprising, since other autoantibodies (i.e. anti-VGCC in 
LEMS) show preferential binding to undifferentiated neuroblastoma cells in a high 
percentage (Waterman, Lang et al. 1997). We could obviously induce the 
autoantigen by differentiation of neuroblastoma cells into a cholinergic phenotype, 
whereas differentiation into a catecholaminergic phenotype by TGF-β1 decreases 
the surface-binding of CRPS sera. These data suggests that the underlying 
autoantigen is highly restricted to distinct neuronal phenotype and may be located 
on special cholinergic neurons. The mutual use of BMP-2 and RA in the presence 
of fetal calf serum has been proved to play a trophic positive role in the 
differentiation of immature cells like SH-SY5Y to cholinergic phenotype neurons 
that express choline acetyltransferase (Gomez-Santos, Ferrer et al. 2002). We 
could additionally show an up-regulation of VAChT expression associated with a 
downregulation of catecholaminergic markers in BMP-2/RA differentiated cells. 
Interestingly, in further experiments, we demonstrated that both β2AR and M2R 
were found to be upregulated in BMP-2/RA differentiated SH-SY5Y neuroblastoma 
cells. This might indicate that the previously detected, but unidentified, cell-surface 
antigen on differentiated autonomic cells must be either β2AR (expressed also in 
sympathetic neurons) and/or M2R.  
Indeed, one problem on CRPS research is the lack of a gold standard. The 
demonstration of autoantibodies in most CRPS patients could be a very promising 
tool on developing markers to make or improve diagnosis, in a more sensitive and 
specific way, as well as to follow the development of the disease or the effect of 
interventions. For more than two decades, the detection of serum autoantibodies 
has been used for the diagnosis and classification of autoimmune diseases. It is 
now clear that many autoantibodies have the ability to predict the development of 
an autoimmune disease and serve as biomarkers for different disease activity. 
Many autoantibodies, produced during an infection far before disease’s onset, are 
detected in the pre-clinical phase of autoimmune diseases many years before the 
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disease becomes apparent (Verge, Gianani et al. 1996; LaGasse, Brantley et al. 
2002; Maclaren, Lan et al. 2003; Scofield 2004; Shoenfeld, Blank et al. 2008).  It 
would be very promising identifying persons at risk to develop CRPS, especially if 
disease onset or progression can be prevented by avoiding environmental factor 
that could work as a trigger. However, further studies are required to optimize 
these methods for the diagnosis of CRPS. 
Further research is also necessary to gain more insight into the clinical significance 
of autoantibodies and their pathogenic mechanisms in CRPS. The clinical picture 
of CRPS is clearly restricted to one (rarely two or three) limb(s), and an 
autoimmune process against two ubiquitously expressed receptors might not 
provide a unifying hypothesis for all CRPS symptoms. However, both β2AR and 
M2R are involved in the modulation of pain and inflammation (Hocking, Smith et 
al.; Diatchenko, Anderson et al. 2006; Hayashida, Bynum et al. 2006; Danielson, 
Andersson et al. 2007).  
One prospective study has reported that haplotypes reflecting variability in eight 
polymorphisms in the β2AR gene were associated with risk for later development 
of a common chronic pain condition (Diatchenko, Anderson et al. 2006). Such 
β2AR polymorphisms also play a role in regulation of vascular tone, and thus may 
be relevant to understand the vasomotor characteristics of CRPS (Brodde and 
Leineweber 2005). Of note, catecholamines regulate the production and release of 
proinflammatory cytokines acting via β2AR on immune cells (Maestroni 2006). 
Activation of the β2AR possess pro-inflammatory properties and mediate increased 
production of proinflammatory cytokines IL-1β and IL-6 by macrophage cell lines 
(Tan, Nackley et al. 2007). 
Recently it has been reported that the cholinergic system has an important role in 
the modulation of nociceptive responses (Haberberger et al, 2004; Rashid et al, 
2006). Under physiological conditions M2R activation on peripheral nociceptors 
interferes with nerve excitability and therefore with release of neuropeptides, the 
major mediators of neurogenic inflammation (Bernardini, Roza et al. 2002). Thus, if 
the immune-mediated inflammation causes changed receptor expression in 
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neurons, this might explain the localized CRPS symptoms.  
Activation of both G protein coupled receptors β2AR (Magne, Couchie et al. 2001) 
and M2R (Sorimachi, Furukawa et al. 1995) by agonists increase intracellular Ca2+ 
concentration mostly mediated by L-type Ca2+ channels. Calcium is an important 
messenger in intracellular signaling mechanisms; therefore, it has been 
contemplated that the agonistic antibodies might have an effect on intracellular 
Ca2+ concentration. The results showed that the purified IgG from patients indeed 
triggered a rapid increase in intracellular Ca2+ concentration in receptor transfected 
cells similar to the response of agonist, while HC IgG did not show any effect at all. 
This change in Ca2+ might result from the agonistic effects of antibodies on G 
protein coupled receptor. A change in Ca2+ concentration is the first feature after 
protein G receptor activation, which initiates and coordinates specific cellular 
activities after a given agonistic stimuli followed by phosphorylation of multiple 
proteins and alteration of gene expression. Calcium is an important intracellular 
messenger that is involved in modulating a vast array of cellular events.  
Autoimmunity against the autonomic nervous system with functional autoantibodies  
against ion channels or receptors that disrupt autonomic or cardiovascular 
functions have been described in many autoimmune diseases including Lambert-
Eaton Myasthenic syndrome (LEMS) (Waterman, Lang et al. 1997), autonomic 
neuropathies (Vernino, Low et al. 2000; Goldblatt, Gordon et al. 2002), 
Scleroderma (Goldblatt, Gordon et al. 2002), Sjögren’s syndrome (Waterman, 
Gordon et al. 2000), and others (Gleicher, Barad et al. 2007; Jackson, Gordon et 
al. 2008; Maciejewska-Rodrigues, Al-Shamisi et al. 2010). LEMS IgGs impair 
transmitter release from parasympathetic and sympathetic neurons through 
downregulation of one or more subtypes of voltage-gated calcium channels 
(Waterman, Lang et al. 1997). Pharmacological overstimulation of beta-receptors 
by beta-agonists has been shown to induce both receptor desensitization and 
internalisation, and to lead to cytotoxicity on cardiomyocytes (Karliner, Simpson et 
al. 1986; Zhang, Kimura et al. 2005). Conversely, we showed CRPS 
autoantibodies did not possess additional properties of inducing either 
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desensitization or downregulation of β2AR or M2R. Besides, pharmacological 
overdriving of G protein receptors can induce disturbances of cell functions and 
lead to an increased cell death rate (Gao, Liu et al. 2006). However, CRPS 
antibodies did not show any cytotoxic effects against receptor transfected cells.  
We addressed a possible cross-reactivity between both functionally active receptor 
autoantibodies. The rational behind that was to prove whether they represent two 
functionally independent receptor antibodies. In Chagas disease, beta1-antibodies 
react with an epitope on the second extracellular domain of  β1AR, but interestingly 
cross-react with an epitope on the M2R (Elies, Ferrari et al. 1996). Nonetheless, 
β2AR or M2R antibodies that coexist in the serum of CRPS patients are two 
entirely distinct antibodies, rather than cross-reacting antibodies. They have been 
proved to belong to different immunoglobulin subclass - β2AR belong to IgG1 and 
IgG2 subtypes whereas M2R antibodies to IgG1 and IgG3 subtypes – and 
therefore probably present different immunological function. 
One may discuss it is very unlikely a syndrome involving symptoms mostly locally 
restricted to the affected extremity to be antibody-mediated. Though the main 
clinical feature of CRPS is limited to one extremity, the involvement of other 
extremities or systemic disturbance in the urogenital (Chancellor, Shenot et al. 
1996), cardiovascular (Meier, Alexander et al. 2006)  and gastrointestinal (Goebel, 
Buhner et al. 2008) system are frequently observed. As likely as not, 
autoantibodies - an important serological feature of CRPS - might induce weak 
systemic but strong localized symptoms if receptor expression in neurons has 
changed locally after trauma.  
Since its first description more than 150 years ago, the pathophysiology of CRPS is 
very complex and still not understood. Some components have been identified 
such as a neurogenic inflammation involving neuropeptides such as substance P 
and CGRP; a disturbance of the sympathetic nervous system, in both peripheral 
and central nervous system, and a cortical reorganization process leading to 
chronic disability. Additionally, a reduction of small-diameter axons in the affected 
area of the limb has also been described (Oaklander, Rissmiller et al. 2006). Here 
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we achieved important progress in understanding the involvement of the immune 
system in this complex symphony of CRPS by proving the coexistence of two 
functionally active autoantibodies against autonomic nervous system receptors in 
the majority of CRPS patients.  
The immune-hypothesis of CRPS has also been supported by different treatment 
effects: IvIg have been shown effective in some patients with CRPS in a 
randomized cross-over trial and in case reports (Goebel, Baranowski et al.; 
Goebel, Stock et al. 2005). Most surface-binding autoantibodies in neurological 
diseases, such as acetylcholine receptor antibodies in myasthenia gravis or 
potassium channel antibodies in limbic encephalitis with obviously pathogenic 
effects respond well to corticosteroids, IvIg or plasmapheresis (Vincent, Buckley et 
al. 2004; Linker and Gold 2008). Thus, immunosuppressive or immune-modulatory 
therapies could represent a promising treatment option in patient with otherwise 
treatment-resistant chronic CRPS, if surface-binding autoantibodies are detectable, 
and therefore worthy to be further investigated. 
We were not able to find any correlation between serological and clinical features. 
Although there were no differences in clinical autonomic symptoms between 
surface binding-antibody-positive and –negative patients; more subtle differences, 
which would need differentiated autonomic testing in forthcoming studies, could not 
be excluded. Since many polyneuropathy patients tested also had medical history 
of chronic pain and none of them showed binding antibodies, the presence of 
receptor binding antibodies seems not to be related to chronic pain, but rather a 
serological feature of CRPS patients. 
The origin of the autoimmune process and its relevance for the pathophysiology of 
CRPS remains to be completely elucidated. It further remains unclear whether the 
autoantibodies are already present before the clinical manifestation of CRPS or 
appeared thereafter. We could not detect these autoantibodies in controls, NL and 
NP indicating that a trauma or nerve lesion alone does not induce specific 
autoimmunity. Regarding the signs of inflammation and the association with 
antimicrobial serology, one may speculate that in CRPS the autoimmune process 
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may be the result of a cross-reactive immunity between viral or bacterial epitopes 
and structures of the autonomic nervous system in genetically predisposed 
individuals. Taken together, the identification of receptor-binding autoantibodies 
directed against the muscarinic M2R and the adrenergic β2AR with functional 
properties provides clear evidence of an autoimmune etiology of CRPS - at least in 
certain patients. We supplied sufficient data to justify further exploration in order to 
gain more insight into the clinical significance of autoantibodies and their 
pathogenic role in CRPS. Thus, huge progress has been achieved in our 
understanding of the pathophysiology of this most complicated pain disorder and 
should additionally foster the rationale for an immune-based treatment approach in 
these patients. 
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VI - SUMMARY 
Complex regional pain syndrome (CRPS) is a painful condition affecting one or 
more extremities of the body, marked by a wide variety of symptoms and sings that 
are often difficult to manage since pathophysiology is incompletely understood. 
Thus, diverse treatments might be ineffective. A recent report revealed the 
presence of autoantibodies against nervous system structures in CRPS patients. 
However it remained unclear how the antibodies act in the development of CRPS. 
We therefore aimed to characterize these antibodies and identify target antigens.  
 
Sera of CRPS patients, neuropathy patients and healthy volunteers were tested for 
surface-binding autoantibodies to primary cultures of autonomic neurons and many 
differentiated neuroblastoma cell lines using flow cytometry. Further, functional 
properties of affinity-purified IgG of controls or CRPS patients were assessed using 
a cardiomyocyte bioassay. Putative receptors and target antigens were identified 
using antagonistic drugs and synthesized peptides sequences corresponding to 
segments of these receptors. Peptides were also used to establish an enzyme 
immunoassay. Antibodies were tested in stable transfected CHO cells with putative 
receptors to ensure observed binding. Further, changes in the intracellular Ca2+ 
concentration induced by agonistic IgG were measured using the Ca2+-sensitive 
fluorescent dye fura-2 assay. Potential cytotoxicity of binding antibodies were 
tested using LDH and WST-1 assay. 
 
13/30 CRPS patients, but none of 30 healthy controls and only one out of 20 
neuropathy sera had specific surface-binding to autonomic neurons. The majority 
of the sera reacted with both sympathetic and myenteric plexus neurons. The 
differentiation of SH-SY5Y into a cholinergic phenotype induced a surface-antigen, 
which is recognized by 60% of CRPS sera (18/30), but not by controls. Moreover, 
ELISA and an established cardiomyocyte assay demonstrated the presence of 
autoantibodies in most CRPS patients with agonistic-like properties on the β2AR 
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and M2R. We identified these autoantibodies as immunoglobulin G directed 
against peptide sequences from the second extracellular loop of these receptors. 
Though antibodies acted on receptors and increase in intracellular Ca2+ 
concentration in transfected cells, they were not able to induce receptor 
downregulation, desensitization or cytotoxicity.  
 
The recent detection of functionally active autoantibodies in serum samples from 
CRPS patients against cell-surface determinants of sympathetic, myenteric and 
differentiated autonomic nervous system neurons, and the identification of these 
determinants as part of β2AR or M2R expressed in these cells suggested an 
autoimmune mechanisms as one important pathogenic factor in the 
pathophysiology of CRPS. Thus, our findings contribute to the understanding of 
this disease, could help in the diagnosis in future, and encourage new treatment 
strategies focusing on the immune system. 
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VII - ZUSAMMENFASSUNG 
Das komplexe regionale Schmerzsyndrom gehört zur Gruppe der chronisch 
posttraumatischen Schmerzsyndromen. Die Krankheit ist gekennzeichnet durch 
regionale, persistierende neuropathische Schmerzen mit sensorischen-, vaso-, 
sudomotorischen-, motorischen- und trophischen Veränderungen nach äußerer 
Einwirkung (z. B. Traumen, Operationen und Entzündungen). Da der 
zugrundeliegende Pathomechanismus des CRPS noch nicht eindeutig geklärt ist, 
sind die Symptomenkomplexe therapeutisch nur symptomatisch beeinflussbar. 
Unserer Gruppe gelang erstmals der Nachweis von Autoantikörpern gegen 
Strukturen des autonomen Nervensystems bei Patienten mit CRPS. Bis heute 
wurde jedoch noch nicht untersucht, in wie weit diese Antikörper eine Rolle bei der 
Entstehung des CRPS spielen könnten. Das Ziel der vorliegend Arbeit war die 
Charakterisierung dieser Antikörper, sowie die Identifizierung der zugehörigen 
Antigene.  
 
In der hier vorgestellten Studie untersuchten wir Seren von gesunden Probanden, 
CRPS- und Polyneuropathie-Patienten auf das Vorliegen relevanter Autoantikörper 
gegen Oberflächenepitopen primärkultivierter autonomer Neuronen und 
differenzierter Neuroblastom-Zellen mittels Durchflusszytometrie. Darüber hinaus 
untersuchten wir mögliche funktionelle Effekte antineuronaler Autoantikörper im 
Bioassay der spontan pulsierenden neonatalen Rattenherzmuskelzellen. Zur 
Identifizierung der Bindungsrezeptoren bzw. Bindungsepitops untersuchten wir den 
Effekt von Rezeptoren-Antagonisten und von kurzen überlappenden Peptiden der 
extrazellulären Schleife verschiedener Rezeptoren. Diese Peptide der 
extrazellulären Schleife autonomer Rezeptoren wurden zur Etablierung eines 
ELISA-Assay  verwendet. Zur Bestätigung der Bindungseigenschaften der 
Autoantikörper wurden stabil transfizierte CHO-Zellen mit Bindungsrezeptoren 
durch Anwendung der Durchflusszytometrie und Imaging-(Fura-2)-Technik 
getestet. 
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Bei 13/30 CRPS-Patienten aber nur bei 1/20 Patienten mit Polyneuropathie und 
bei keiner Kontrolle konnte die Bindung von IgG an der Oberfläche 
primärkultivierter autonomer Neuronen durchflusszytometrisch nachgewiesen 
werden. Die meisten Seren reagierten sowohl mit Neuronen aus sympathischen 
Ganglien, wie auch kultivierten Darmplexusneuronen. 18/30 der CRPS- aber keine 
Kontroll-Seren erkannten eine Epitop erzeugt durch Differenzierung von SY5Y zum 
cholinergischen Phänotyp. Unsere Ergebnisse zeigten, dass die Mehrheit der 
CRPS-Patienten stimulierende Antikörper gegen β2AR und M2R aufweisen. Der 
Nachweis der Autoantikörper erfolgte mittels ihres chronotropen Effekts auf die 
Pulsationsrate der Herzmuskelzellen sowie dessen Blockierung durch den 
adrenergen β2-Blocker, den  M2-Antagonist und synthetische gegen die 2. 
extrazelluläre Schleife der  beiden Rezeptoren gerichtete Peptide. Diese Daten 
wurden durch erhöhte Bindung patogenischer Antikörper zu der Oberfläche β2AR 
und M2R transfizierter Zellen bestätigt. Obwohl durch die Imaging-(Fura-2)-
Technik der stimulierende Antikörpereffekt wieder bestätigt wurde, führte keine 
untersuchte IgG-Fraktionen von CRPS-Patienten zu zellbiologischen 
Veränderungen wie Zytotoxizität oder Rezeptor-Desensitisierung bzw. -
Downregulation. 
 
Die von uns nachgewiesenen funktionellen Effekte antineuronaler Autoantikörper 
von CRPS-Patienten gegen primärkultivierter und differenziert autonomer 
Neuronen und der Charakterisierung stimulierender Autoantikörper gegen 
Peptiden der zweiten extrazellulären Schleife der β2AR und M2R deutet darauf 
hin, dass Immunmechanismen in der Pathogenese des CRPS, möglicherweise 
durch eine Autoimmunreaktion gegen das autonome Nervensystem eine wichtige 
Rolle spielen könnten. Unsere Erkenntnisse bieten einen Einblick in mögliche 
pathophysiologische Mechanismen bei der Entstehung von CRPS. Sie könnten als 
Basis für neue Überlegungen über diagnostische Methoden und den Einsatz 
immunmodulierender Therapiestrategien dienen. 
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XI – APPENDIX 
Appendix 1. Table displaying the binding of each tested patient to peptides of β2AR and/or M2R  
detected using ELISA. 
β2AR Peptides M2R Peptides 
ID 
CRPS 
type* 
CRPS 
Warm/Cold* HWYRAT ATHQEAI AINCYAN VRTVED EDGECY CYIQFF
A 2 Cold - - - + + - 
B 1 Warm - - - + + - 
C 2 Warm - - - - + - 
D 1 Cold - - - - + - 
E 1 Warm + - - + + - 
K 2 Warm - + - - + - 
L 2 Warm + + - + + - 
M 2 Warm - - - + + - 
N 2 Warm - - - - - - 
T 2 Cold - - - - + - 
V 2 Warm + + - + - - 
W 2 Warm + + - + + - 
X 2 Cold - + - + + - 
Y 2 Cold + + - - + - 
6 1 Warm + + - + + - 
7 1 Warm + + - + - - 
8 1 Warm + + - + + - 
9 1 Warm + + - + + - 
10 1 Warm + + - + + - 
11 1 Warm - - - - - - 
*There were no significance between CRPS type or warm/cold and positive binding to any tested peptide (Fisher’s exact 
test, p > 0.05). 
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Appendix 2. Changes in the intracellular Ca2+ concentration induced by CRPS autoantibodies or 
agonist in hβ2AR-CHO. CRPS autoantibodies and β2-agonist clenbuterol (30 µM) induced an 
increase of the fura-2 signal in hβ2AR-CHO cells. For statistics see text. 
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Appendix 3. Changes in the intracellular Ca2+ concentration induced by autoantibodies of CRPS 
patients in hβ2AR-CHO after pre-treatment with antagonist propranolol. Pre-treatment with 1 µM 
propranolol inhibited the effect of IgG (60 mg/L) and of the agonist clenbuterol (30 µM), IgG effect 
on the β2AR could be blocked by propranolol (1 µM) in 5/6 samples. For statistics see text. 
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Appendix 4. Changes in the intracellular Ca2+ concentration induced by CRPS autoantibodies or 
agonist in hM2R-CHO. (A) 2/6 CRPS IgG (60 mg/L) and the agonist bethanechol (100 µM) induced 
a prominent increase in the fura-2 ratio. (B) Both CRPS samples are blocked by preceding 
treatment with the antagonist atropine (1 µM). For statistics see text. 
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